Original Article
Postmenopausal Estrogen Therapy and Cardiovascular Disease — Ten-Year Follow-up from the Nurses' Health Study
N Engl J Med 1991; 325:756-762September 12, 1991
- Abstract
- Abstract
Background.
The effect of postmenopausal estrogen therapy on the risk of cardiovascular disease remains controversial. Our 1985 report in the Journal, based on four years of follow-up, suggested that estrogen therapy reduced the risk of coronary heart disease, but a report published simultaneously from the Framingham Study suggested that the risk was increased. In addition, studies of the effect of estrogens on stroke have yielded conflicting results.
Methods.
We followed 48,470 postmenopausal women, 30 to 63 years old, who were participants in the Nurses' Health Study and who did not have a history of cancer or cardiovascular disease at base line. During up to 10 years of follow-up (337,854 person-years), we documented 224 strokes, 405 cases of major coronary disease (nonfatal myocardial infarctions or deaths from coronary causes), and 1263 deaths from all causes.
Results.
After adjustment for age and other risk factors, the overall relative risk of major coronary disease in women currently taking estrogen was 0.56 (95 percent confidence interval, 0.40 to 0.80); the risk was significantly reduced among women with either natural or surgical menopause. We observed no effect of the duration of estrogen use independent of age. The findings were similar in analyses limited to women who had recently visited their physicians (relative risk, 0.45; 95 percent confidence interval, 0.31 to 0.66) and in a low-risk group that excluded women reporting current cigarette smoking, diabetes, hypertension, hypercholesterolemia, or a Quetelet index above the 90th percentile (relative risk, 0.53; 95 percent confidence interval, 0.31 to 0.91). The relative risk for current and former users of estrogen as compared with those who had never used it was 0.89 (95 percent confidence interval, 0.78 to 1.00) for total mortality and 0.72 (95 percent confidence interval, 0.55 to 0.95) for mortality from cardiovascular disease. The relative risk of stroke when current users were compared with those who had never used estrogen was 0.97 (95 percent confidence interval, 0.65 to 1.45), with no marked differences according to type of stroke.
Conclusions.
Current estrogen use is associated with a reduction in the incidence of coronary heart disease as well as in mortality from cardiovascular disease, but it is not associated with any change in the risk of stroke. (N Engl J Med 1991; 325:756–62.)
Media in This Article
Table 1
Distribution of Characteristics and Coronary Risk Factors Reported by the Women in the Cohort, According to Postmenopausal Hormone Use, with Standardization for Age.*Table 2
Relative Risk of Cardiovascular Disease among Current and Former Postmenopausal Hormone Users, as Compared with Those Who Never Used Postmenopausal Hormones, after Adjustment for Age and Multiple Risk Factors.*Article Activity
- Article
THE influence of exogenous hormones on the risk of cardiovascular disease has long been controversial. More than 20 studies published in the past decade have addressed the issue of postmenopausal estrogen use and coronary disease.1 Our earlier report of a benefit from estrogen use in terms of the risk of coronary disease, based on four years of follow-up,2 was accompanied by a report from the Framingham Study that came to the opposite conclusion.3 These disparate findings led to considerable confusion.4 We now report results for both coronary disease and stroke, based on 10 years of follow-up in the Nurses' Health Study, a large cohort study that included 48,470 postmenopausal women with 337,252 person-years of follow-up.
Methods
The Nurses' Health Study Cohort
The Nurses' Health Study began in 1976, when 121,700 female registered nurses in the United States completed questionnaires sent to them by mail about their medical history, including previous cardiovascular disease, menopause, diabetes, hypertension, high serum cholesterol levels, and parental myocardial infarction. We included questions on height, weight, smoking, the use of postmenopausal hormones, and the use of oral contraceptives.5 Every two years, follow-up questionnaires were mailed to obtain updated information and identify newly diagnosed major illnesses. A dietary questionnaire was added in 1980.6
Ascertainment of Estrogen Use
In 1976 the women were asked whether they had taken hormone supplements after menopause, and if so, for how long. Information on hormone use, including the type taken, was updated in the subsequent questionnaires sent every two years through 1986, with explicit questions about current use and duration of use in the intervening period. Because no information on current use was explicitly requested on the 1976 questionnaire, we considered women to have been current estrogen users for the 1976–1978 period if the duration of their estrogen use was equal (within 12 months) to the interval between menopause and the date of completion of the questionnaire. Women whose duration of hormone use was more than 12 months shorter than this interval were considered former users. The daily dose of conjugated estrogens was obtained beginning in 1980.
Identification and Confirmation of Cardiovascular End Points
The study end points included nonfatal myocardial infarction, fatal coronary heart disease, coronary-artery bypass grafting or angioplasty, fatal and nonfatal stroke, total cardiovascular mortality, and deaths from all causes after the return of the 1976 questionnaire but before June 1, 1986. Nurses who reported having a nonfatal myocardial infarction or stroke on a follow-up questionnaire were asked for permission for a study investigator to review their medical records. Nonfatal myocardial infarctions were considered confirmed by hospital records if they met the World Health Organization criteria7 (i.e., symptoms plus either cardiac-enzyme elevations or diagnostic electrocardiographic changes). Myocardial infarctions that required hospitalization and for which confirmatory information was obtained by interview or letter, but for which no medical records were obtainable, were designated as probable. Thus, infarctions of indeterminate duration discovered on routine examination were not included. Coronary-artery surgery was ascertained by the participants' reports alone.
Nonfatal strokes were considered confirmed by a review of medical records if they were characterized by a typical neurologic deficit, rapid in onset and lasting at least 24 hours, and if they met the criteria of the National Survey of Stroke.8 We classified strokes as ischemic strokes (thrombotic or embolic occlusion of a cerebral artery), subarachnoid hemorrhages, or intraparenchymal hemorrhages. We excluded subdural hematomas and strokes caused by infection or neoplasia. Strokes reported on the questionnaires that required hospitalization and were confirmed by information from a letter or telephone call, but for which the medical records were unavailable, were designated as probable.
Most deaths were reported by the participants' families. We used the National Death Index9 to identify deaths among the nonrespondents to each two-year questionnaire; the mortality follow-up was more than 98 percent complete. For all deaths possibly attributable to cardiovascular causes, we requested permission from the next of kin (subject to state regulations) to review the medical records. Deaths were considered to be due to coronary disease if the medical records or autopsy findings confirmed that a fatal myocardial infarction had occurred. The category of coronary death also included cases in which coronary disease was listed on the death certificate as the underlying cause without another, more plausible cause and in which the nurse was known (e.g., on the basis of the hospital record or an interview with her next of kin) to have had coronary disease before death. In no case was the cause listed on the death certificate used as the sole criterion for a determination of coronary death. We classified strokes as fatal if they were documented by autopsy findings or hospital records or if stroke was listed as the underlying cause of death on the death certificate.
The category of cardiovascular mortality included deaths from stroke, deaths from coronary disease, sudden deaths (death within one hour of the onset of symptoms in an apparently healthy woman), and deaths for which coronary disease was listed as the underlying cause and no more plausible cause could be assigned, but for which confirmation was lacking. Major cardiovascular disease was defined to include both death from cardiovascular disease and nonfatal myocardial infarction and stroke. All the interviews and reviews of medical records were conducted without the investigators' knowledge of the category of estrogen use.
Population for Analysis
Women for whom information on hormone use was missing (3.6 percent of all respondents) were excluded from the analysis. Because women with diagnosed cardiovascular disease may alter their hormone use and are also at increased risk for progression of the disease, their inclusion could distort the results. We therefore excluded from the analysis all women who reported a diagnosis of any cardiovascular disease or cancer (except skin cancer other than melanoma) on the 1976 questionnaire. Similarly, women who reported such a diagnosis on a subsequent questionnaire were excluded from further analysis. Thus, at the start of each two-year interval, the base population included no women reporting these diagnoses. For the analyses of mortality from all causes, however, these women were included, so that deaths due to illnesses lasting more than two years could be considered.
We classified women as postmenopausal from the time they reported having a natural menopause or undergoing hysterectomy with bilateral oophorectomy. Women who underwent hysterectomy without bilateral oophorectomy were considered postmenopausal when they reached the age at which natural menopause had occurred in 90 percent of the cohort (54 years for smokers and 56 for nonsmokers). The women's reports of reaching menopause were highly accurate in this cohort.10
In 1976, a total of 22,950 postmenopausal women entered the analysis for the 1976—1978 period. The population was expanded to include women who became postmenopausal subsequently and were free of cancer and cardiovascular disease. During the 10-year period from 1976 through June 1, 1986, we accrued 337,854 person-years of follow-up among 48,470 women. The follow-up of the cohort, calculated as a percentage of the total potential person-years of follow-up, was 88.4 percent complete for nonfatal outcomes; for mortality, it was more than 98 percent complete. Follow-up rates were quite similar within the different categories of hormone use.
Statistical Analysis
For each participant, person-months were allocated to the categories of hormone use according to the data reported in 1976 and updated at each two-year interval according to information obtained subsequently. Follow-up for a participant ended with a diagnosis of cardiovascular disease or death. If no questionnaire was returned for a two-year follow-up period, the most recent data were applied to the subsequent follow-up interval. If a woman's previous status had been current hormone use, however, she was classified in the update as having used hormones at some time, but current or former use was not specified.
We calculated the relative risk associated with hormone use, defined as the incidence rate of cardiovascular disease among hormone users (estimated as the number of events divided by the person-time of follow-up for the hormone users) divided by the corresponding rate among women who had never used hormones. Age-specific rates of cardiovascular disease for users and nonusers were calculated in five-year categories and used to compute age-adjusted relative risks with 95 percent confidence intervals.11 To adjust for a number of risk factors simultaneously, we used proportional-hazards models.12 All P values are two-tailed.
Results
Women currently using postmenopausal hormones accounted for 21.8 percent of the total follow-up time of 337,854 person-years. Former hormone users accounted for 25.2 percent of the time, and women who had never used hormones 53 percent. In all three groups, potential risk factors for cardiovascular disease were distributed in generally similar patterns. Table 1Table 1
Distribution of Characteristics and Coronary Risk Factors Reported by the Women in the Cohort, According to Postmenopausal Hormone Use, with Standardization for Age.* shows the age-standardized proportions of women who reported various characteristics and coronary risk factors according to their estrogen-use status, on the basis of cumulative person-years from 1976 through 1986. Table 1 also shows the mean intake of various nutrients, with adjustment for energy intake,13 and the proportion of women reporting a period of vigorous exercise at least once per week, both of which were ascertained in 1980. Estrogen users were less likely to have diabetes and more likely to be lean, to engage in regular, vigorous physical activity, to have had a surgical menopause, and to have used oral contraceptives in the past.Among the postmenopausal women who reported no previous cardiovascular disease, we documented 293 nonfatal myocardial infarctions (228 confirmed and 65 probable), 112 confirmed deaths from coronary disease, and 224 strokes (52 fatal and 172 nonfatal; 177 confirmed and 47 probable) during the 10 years of follow-up. Of the strokes, 113 were ischemic strokes and 36 were subarachnoid hemorrhages; the remaining strokes were of other or unknown types. There were 41 other deaths from cardiovascular causes, for a total of 205 cardiovascular deaths. Coronary-artery surgery or angioplasty was reported by 185 women. In the analyses of total mortality, which included women in whom illnesses developed during follow-up, there were 1263 deaths from all causes. No material differences were observed in any of the analyses between the confirmed and the probable categories of myocardial infarction and stroke or between the fatal and the nonfatal categories of coronary disease or stroke; we therefore merged these categories into two larger categories: major coronary disease (nonfatal myocardial infarction and death from coronary causes) and total stroke.
Overall, the age-adjusted risk of major coronary disease among current estrogen users was about half that of women who had never used estrogen, with a relative risk of 0.51 (95 percent confidence interval, 0.37 to 0.70; P<0.0001) (Table 2Table 2
Relative Risk of Cardiovascular Disease among Current and Former Postmenopausal Hormone Users, as Compared with Those Who Never Used Postmenopausal Hormones, after Adjustment for Age and Multiple Risk Factors.*). For former users, the age-adjusted relative risk was 0.91 (95 percent confidence interval, 0.73 to 1.14; P = 0.42). In contrast, we observed no association between current estrogen use and total stroke. The age-adjusted relative risk was 0.96 (95 percent confidence interval, 0.67 to 1.37) and was virtually unchanged after further adjustment for other cardiovascular risk factors. No material associations were observed for ischemic stroke or subarachnoid hemorrhage; there were too few cases of intraparenchymal hemorrhage for analysis.We observed no apparent association between estrogen use and the incidence of coronary-artery surgery. Among the current users, the age-adjusted relative risk was 1.21 (95 percent confidence interval, 0.84 to 1.73), and for former users it was 0.86 (95 percent confidence interval, 0.60 to 1.22). Among the former users, there were no notable trends with regard to duration of use or time since most recent use. Simultaneous adjustment for other risk factors in multivariate analyses had virtually no effect on these estimates. We found no evidence to suggest that the degree of protection associated with current estrogen use was related to the duration of use, independent of age, for any of the end points; among the former users, the period of time since the cessation of estrogen use was not consistently related to the risk of cardiovascular outcomes (data available elsewhere*).
The study had insufficient statistical power to determine the effects of specific forms of hormone therapy other than unopposed oral conjugated estrogen. Of the 57,570 person-years of follow-up for current hormone users from 1978 through 1986, 71.5 percent involved the use of unopposed oral conjugated estrogen, 11.5 percent other estrogens, 2.7 percent estrogens with progestin, 2.2 percent other hormones, and 12 percent hormones of unknown type (or information was missing). The age-adjusted relative risk of major coronary disease with current use of unopposed oral conjugated estrogen was 0.40 (95 percent confidence interval, 0.26 to 0.62).
Information about the dose of conjugated estrogen was available for the period from 1980 through 1986. The only marked difference in the association observed with different dose levels was an apparent increase in the risk of coronary disease among women taking more than 1.25 mg per day (relative risk, 2.8; 95 percent confidence interval, 0.9 to 8.2), as compared with the substantial decrease in risk among those taking lower doses. The use of estrogen at doses of more than 1.25 mg per day was very uncommon (4 percent of the cohort), however, and the relative risk is based on only three cases.
We assessed whether the inverse association of estrogen use with the risk of coronary disease differed for women with different characteristics. We observed few marked differences in the associations. The age-specific relative risk appeared to show a nonsignificant trend (P = 0.19) toward more protection from coronary disease among younger postmenopausal hormone users. For the oldest age group, women 60 to 64 years of age, the relative risk was 1.35 (95 percent confidence interval, 0.65 to 2.82). We noted possible tendencies toward more protection among smokers than among nonsmokers, among women without a parental history of myocardial infarction before the age of 60, and among the leanest women, but these differences in relative risks were not statistically significant.* Among the women who had a natural menopause, the age-adjusted relative risk of major coronary disease for current estrogen users was 0.62 (95 percent confidence interval, 0.39 to 0.97), not as low as the risk for women who underwent bilateral oophorectomy (relative risk, 0.40; 95 percent confidence interval, 0.22 to 0.73).
To evaluate the effect of estrogen use among women at low risk, we defined a subgroup of women who were not current smokers; had no hypertension, diabetes, or high serum cholesterol level; and had a Quetelet index below 32, the 90th percentile for this cohort. For this group, the age-adjusted relative risk of major coronary disease among current hormone users was 0.53 (95 percent confidence interval, 0.31 to 0.91).
To adjust for the effects of several potential risk factors simultaneously, we used proportional-hazards models to estimate the relative risks associated with current and former use of estrogens, controlling for age, follow-up period, and the characteristics listed in Table 1. Because the current estrogen users were slightly healthier, this adjustment attenuated the apparent benefit slightly. The results (shown as adjusted for age and risk factors) were similar to those obtained after adjustment for age alone; for major coronary disease, the relative risk among current users was 0.56 (95 percent confidence interval, 0.40 to 0.80) (Table 2). A model that also included age at menopause as a continuous variable yielded virtually the same estimates. Similar models that included the data on dietary intake and physical activity yielded similar findings, although the estimates were less precise because only data for 1980 through 1986 could be included.
To assess whether receiving more medical care might account for the benefit in postmenopausal estrogen users, we repeated the analysis, limiting it to women who reported having visited a physician in 1978 (65 percent of the cohort). The results were similar to those for the population as a whole: the age-adjusted relative risks of major coronary heart disease were 0.45 (95 percent confidence interval, 0.31 to 0.66) for current estrogen users and 0.79 (95 percent confidence interval, 0.60 to 1.05) for former users. For cardiovascular mortality, the age-adjusted relative risks were 0.52 (95 percent confidence interval, 0.40 to 0.69) for current users and 0.77 (95 percent confidence interval, 0.62 to 0.95) for former users.
In analyzing mortality from all causes, we focused primarily on women who had used estrogen at any time, in order to avoid the potential problem created by shifts in status from current to former use as a result of a diagnosis of disease. We also eliminated the requirement that the cohort be free of diagnosed cancer and heart disease at the beginning of each two-year period; this allowed us to include deaths due to illnesses lasting more than two years. Thus, in this analysis, the cohort was free from diagnosed cancer and heart disease at base line in 1976 (or at entry into the analysis, for those who became postmenopausal later) and was followed until death or the cutoff date of May 31, 1986. For women who had used estrogens at any time, the age-adjusted relative risk of mortality from all causes was 0.81 (95 percent confidence interval, 0.72 to 0.91; P = 0.0004); for cardiovascular mortality, it was 0.68 (95 percent confidence interval, 0.52 to 0.90). After adjustment for other risk factors, the relative risks were slightly attenuated, but they remained statistically significant; for total mortality, the risk was 0.89 (95 percent confidence interval, 0.78 to 1.00), and for cardiovascular mortality it was 0.72 (95 percent confidence interval, 0.55 to 0.95; P = 0.02). Because in the earlier analyses benefits had been found to be attributable to current estrogen use, this analysis underestimated the benefit of estrogen by including former users with current users. To remove this bias in part, we excluded women who had already discontinued estrogen use at base line but not those who used estrogen at base line and discontinued it later. The exclusion of the latter group would have led to an overestimate of the benefit, because estrogen therapy is often discontinued in women who have potentially fatal illnesses, such as breast cancer.
Discussion
In this prospective study of 48,470 women, we observed that when current postmenopausal estrogen users were compared with women who had never used estrogen, they had about half the risk of major coronary disease or fatal cardiovascular disease and no increase in the risk of stroke. The prospective study design virtually eliminated the biases in recall and selection that can affect case–control studies. The follow-up rate was high, particularly for fatal outcomes, reducing the likelihood that differential follow-up could have affected the results.
Information on exposure to estrogen and other potential risk factors was derived from reports by the women themselves, but we believe them to be reliable. The reports have been validated by a review of the medical records and by direct measurement with respect to several conditions.6 , 14 Also, the risk factors reported by the subjects were strong predictors of subsequent cardiovascular disease,2 , 5 , 15 , 16 and the subjects were all registered nurses with a demonstrated interest in medical research.
The most plausible alternative to a cause—effect relation between estrogen use and the reduced risk of coronary disease is that healthier women are selected for such therapy. In this cohort, however, the estrogen users appeared only slightly healthier than the nonusers and were generally similar to them with respect to most cardiovascular risk factors. The estrogen users had a much higher incidence of bilateral oophorectomy, a coronary risk factor only for women not receiving estrogen-replacement therapy.17 , 18 The estrogen users also tended to be leaner, which may result in lower levels of estrogen from adipose tissue.19 The likelihood of lower levels of endogenous estrogen in thinner women is consistent with the trend toward a greater benefit from postmenopausal estrogen with respect to coronary disease in that group, but the protection associated with estrogen use was present in women in all categories of the Quetelet index. The stratified and multivariate proportional-hazards models indicated only minor overall confounding, as judged by the similarity of the relative risks after adjustment for age alone with those that took account of other risk factors. The similar benefit in the analysis limited to women who reported a recent visit to a physician suggests that access to medical care appeared to have little effect on estimates of the effect of estrogen on the risk of cardiovascular disease.
The apparent marked benefit of estrogen in reducing the risk of coronary disease is consistent with previous evidence. Of 15 other prospective studies, 14 found decreased risks among estrogen users.1 The Framingham Study alone found an elevated risk,3 which was not statistically significant when women with angina were omitted. A subsequent reanalysis of the Framingham data showed a nonsignificant protective effect among younger women but a nonsignificant adverse effect among older women.20 Similarly, all three cross-sectional studies of coronary angiography showed substantially less atherosclerosis among estrogen users.21 22 23 A quantitative overview of previous studies taken together yielded a relative risk of 0.56 (95 percent confidence interval, 0.50 to 0.61); when only the analytic prospective and angiographic studies were considered, the relative risk was 0.50 (95 percent confidence interval, 0.43 to 0.56).1
The nonsignificant trend in our data toward a decreasing benefit of estrogen with increasing age is consistent with the Framingham data,3 , 20 but Henderson et al. found a substantial reduction in risk among women in their 70s.28 Future follow-up will clarify this issue, but the weight of the evidence suggests a protective effect among postmenopausal women of all ages. In the analysis of women with a favorable risk-factor profile, the observed age-adjusted relative risk of major coronary disease, 0.53, was virtually identical to that for the whole cohort. This implies that women at lower risk enjoy the same relative benefit from estrogen as women in general. Because rates of coronary disease were lower among the low-risk women, however, the same relative decrease corresponded to a smaller reduction in the number of events.
As in other studies,1 we found that the benefit of therapy was evident primarily among current estrogen users, and there was no indication of an effect of the duration of use independent of age. The best-supported mechanism is the markedly favorable effect of estrogen on serum lipids: estrogens raise the level of high-density lipoprotein cholesterol and lower that of low-density lipoprotein cholesterol. Although estrogen-induced changes in lipid metabolism are sufficient to explain a large reduction in the risk of coronary disease,24 other plausible mechanisms have been proposed.25 We observed less benefit, and perhaps an adverse effect, among women taking more than 1.25 mg of estrogen daily. Such high doses were common in the Framingham cohort, which may partly explain their discrepant results.
The absence of an association between estrogen use and the incidence of coronary-artery surgery was unexpected, particularly in view of evidence from cross-sectional angiographic studies showing a strong association of estrogen use with a reduction in atherosclerosis.21 22 23 Perhaps women taking estrogens under closer medical supervision are more likely to undergo coronary surgery when they have a given level of symptoms than women not taking estrogens.
We found no effect of estrogens on the incidence of total stroke or that of ischemic stroke and subarachnoid hemorrhage. In the Leisure World Study, Paganini-Hill et al.26 did find a decrease in risk, but the benefit may have been overestimated because patients with previous cardiovascular disease, who may be more prone to strokes and less likely to have estrogen prescribed, were not excluded. However, this can explain only part of the observed benefit. The Framingham Study3 found an adverse effect of using estrogen at any time on the risk of stroke, whereas the large, prospective Copenhagen Study27 found little effect either way. Both the Copenhagen Study and our own study included mostly middle-aged women, as compared with the Leisure World Study,26 in which the median age was 73; perhaps the protective effect is limited to older women.
In analyses of total mortality, it is important to exclude subjects at the start of follow-up who have life-threatening diseases. Because women with such diseases (e.g., breast cancer) are both less likely to be prescribed estrogen and more likely to die within a given period, their inclusion in an analysis would exaggerate any benefit of estrogen. Similarly, an analysis restricted to women who continue to use estrogen would have the same effect, because women who acquire certain life-threatening conditions may be advised to cease hormone use. In our analysis, which took those considerations into account, we observed an age-adjusted relative risk of 0.81 (95 percent confidence interval, 0.72 to 0.91) and a multivariate relative risk of 0.89 (95 percent confidence interval, 0.78 to 1.00). The relative risk of cardiovascular mortality in women with any estrogen use, after adjustment for other risk factors, was 0.72 (95 percent confidence interval, 0.55 to 0.95). The benefit with respect to mortality from all causes is likely to be an underestimate, because the effects of estrogen-induced protection from hip fracture and its associated mortality would be more pronounced at an older age. Indeed, in the Leisure World Study, a relative risk of 0.64 (95 percent confidence interval, 0.52 to 0.78) was found for total mortality among current estrogen users,28 but this was probably an overestimate of the true benefit, because women with prevalent disease were not omitted at base line. Bush et al. reported a relative risk of 0.54 among estrogen users for mortality from all causes,29 but their result may also have overestimated the benefit, for the same reason. Petitti et al. reported a relative risk of total mortality of 0.8 (95 percent confidence interval, 0.6 to 1.1) in a follow-up study of healthy women.30
The consistency of the epidemiologic data, the apparent absence of important confounding or selection bias, and biologic plausibility24 , 25 all suggest a causal association between estrogen use and a reduced risk of coronary disease. Further work is needed to identify the women most likely to benefit from hormone therapy, as well as the effect of added progestins. Proposed clinical trials among women with established coronary disease will be useful. The findings regarding mortality from all causes as well as risk—benefit analyses31 32 33 suggest that, overall, the benefits of postmenopausal estrogen therapy outweigh the risks,34 even apart from the substantial benefits in alleviating menopausal symptoms. These risks include an increase in the rate of endometrial cancer, which can be completely or largely blocked by the addition of a progestin, and possibly some increase in the incidence of breast cancer.
The risk—benefit assessment will differ according to a given woman's medical condition and nonmedical characteristics (including the fear of cancer), so we make no global recommendations. The decision must be made by the individual woman and her physician after they evaluate all the relevant benefits and risks.
Supported by research grants (HL 34594 and CA 40356) from the National Institutes of Health.
We are indebted to the participants in the Nurses' Health Study for their continuing cooperation, and to Stefanie Bechtel, Karen Corsano, Gary Chase, Sue-Wei Chiang, Barbara Egan, Marion McPhee, Mark Shneyder, Debbie O'Sullivan, and Susan Newman for their expert help.
Source Information
From the Channing Laboratory, Departments of Medicine (M.J.S., G.A.C., W.C.W., J.E.M., B.R., F.E.S., C.H.H.) and Preventive Medicine (B.R., C.H.H.), Harvard Medical School and Brigham and Women's Hospital, and the Departments of Epidemiology (M.J.S.,G.A.C., W.C.W.), Nutrition (W.C.W.), Biostatistics(B.R.), and Environmental Health (F.E.S.), Harvard School of Public Health, all in Boston. Address reprint requests to Dr. Stampfer at Channing Laboratory, 180 Longwood Ave., Boston, MA 02115.
- References
References
*
See NAPS document no. 04890 for eight pages of supplementary material. Order from NAPS c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163–3513. Remit in advance (in U.S. funds only) $7.75 for photocopies or $4 for microfiche. Outside the U.S. and Canada add postage of $4.50 ($1.50 for microfiche postage). There is a $15 invoicing charge on all orders filled before payment.
1
Stampfer
CrossRef | Web of Science | Medline2
Stampfer
Full Text | Web of Science | Medline3
Wilson
Full Text | Web of Science | Medline4
Bailar
Full Text | Web of Science | Medline5
Colditz
Web of Science | Medline6
Willett
Web of Science | Medline7
World Health Organization. IHD registers: report of the fifth working group. Copenhagen, Denmark: World Health Organization, 1971.
8
Walker 9
Stampfer
Web of Science | Medline10
Colditz
CrossRef | Web of Science | Medline11
Rothman KJ, Boice JD Jr. Epidemiologic analysis with a programmable calculator. Washington, D.C.: Public Health Service, 1979. (NIH publication no. 79–1649.)
12
Cox 13
Willett
Web of Science | Medline14
Colditz
Web of Science | Medline15
Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Coronary heart disease risk factors in women: the Nurses' Health Study experience. In: Eaker E, Packard B, Wenger NK, Clarkson TB, Tyroler HA, eds. Coronary heart disease in women. New York: Haymarket Doyma, 1987:112–6.
16
Colditz 17
Colditz
Full Text | Web of Science | Medline18
Stampfer
CrossRef | Web of Science | Medline19
Judd
Web of Science | Medline20
Eaker ED, Castelli WP. Coronary heart disease and its risk factors among women in the Framingham Study. In: Eaker E, Packard B, Wenger NK, Clarkson TB, Tyroler HA, eds. Coronary heart disease in women. New York: Haymarket Doyma, 1987:122–32.
21
Sullivan
Web of Science | Medline22
Gruchow
CrossRef | Web of Science | Medline23
McFarland
CrossRef | Web of Science | Medline24
Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell D, ed. Menopause: physiology and pharmacology. Chicago: Year Book Medical. 1986:187–208.
25
Lobo
CrossRef | Web of Science | Medline26
Paganini-Hill
CrossRef | Web of Science | Medline27
Boysen
CrossRef | Web of Science | Medline28
Henderson
CrossRef | Web of Science | Medline29
Bush
CrossRef | Web of Science | Medline30
Petitti
Web of Science | Medline31
Henderson
Web of Science | Medline32
Hillner
CrossRef | Web of Science | Medline33
Weinstein
CrossRef | Medline34
Colditz
CrossRef | Web of Science | Medline
- Citing Articles (597)
Citing Articles
1
Geer Mohammad Ishaq, Pz Tasaduq Hussain, Mir Javid Iqbal, Mohsin Bin Mushtaq. (2013) Risk-Benefit Analysis of Combination Versus Unopposed HRT in Post-Menopausal Women. International Journal of User-Driven Healthcare 1:4, 61-76
CrossRef2
Haruki Sekiguchi, Masaaki Ii, Kentaro Jujo, Marie-Ange Renault, Tina Thorne, Trevor Clarke, Aiko Ito, Toshikazu Tanaka, Ekaterina Klyachko, Yasuhiko Tabata, Nobuhisa Hagiwara, Douglas Losordo. (2012) Estradiol triggers sonic-hedgehog-induced angiogenesis during peripheral nerve regeneration by downregulating hedgehog-interacting protein. Laboratory Investigation
CrossRef3
Helen Valentine, Erin K. Daugherity, Bhupinder Singh, Kirk J. Maurer. 2012. The Experimental Use of Syrian Hamsters. , 875-906.
CrossRef4
I. Lambrinoudaki, A. Augoulea, E. Armeni, D. Rizos, A. Alexandrou, M. Creatsa, M. Kazani, G. Georgiopoulos, A. Livada, A. Exarchakou, K. Stamatelopoulos. (2011) Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. Climacteric1-8
CrossRef5
Wendy Keung, Matthew L.Y. Chan, Eva Y.W. Ho, Paul M. Vanhoutte, Ricky Y.K. Man. (2011) Non-genomic activation of adenylyl cyclase and protein kinase G by 17β-estradiol in vascular smooth muscle of the rat superior mesenteric artery. Pharmacological Research 64:5, 509-516
CrossRef6
Paul W. Stewart, Jacqueline Reihman, Edward Lonky, James Pagano. (2011) Issues in the interpretation of associations of PCBs and IQ. Neurotoxicology and Teratology
CrossRef7
Michelle E. Koski, Christopher J. Chermansky. (2011) Does Estrogen Have Any Real Effect on Voiding Dysfunction in Women?. Current Urology Reports 12:5, 345-350
CrossRef8
Amanda N. Kallen, Lubna Pal. (2011) Cardiovascular disease and ovarian function. Current Opinion in Obstetrics and Gynecology 23:4, 258-267
CrossRef9
T. Yoshida, K. Takahashi, H. Yamatani, K. Takata, H. Kurachi. (2011) Impact of surgical menopause on lipid and bone metabolism. Climacteric 14:4, 445-452
CrossRef10
Dawn M Meyer, Jo-Ann Eastwood, Margaret P Compton, Karen Gylys, Justin A Zivin, Bruce Ovbiagele. (2011) Sex differences in antiplatelet response in ischemic stroke. Women's Health 7:4, 465-474
CrossRef11
Donna Shoupe. (2011) Individualizing hormone therapy to minimize risk: accurate assessment of risks and benefits. Women's Health 7:4, 475-485
CrossRef12
David R. Rubinow, Susan S. Girdler. (2011) Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater. Depression and Anxiety 28:6, E1-E15
CrossRef13
Karen Roush. (2011) Menopausal Hormone Therapy: What We Know Now. AJN, American Journal of Nursing 111:6, 38-47
CrossRef14
Ainhoa Ruiz del Agua, Igor Aurrekoetxea, Miguel Angel Elorriaga, Fernando Rodriguez, Françoise Guéraud, M. Begoña Ruiz-Larrea, José Ignacio Ruiz-Sanz. (2011) Involvement of G-463A MPO gene polymorphism in the response of postmenopausal women to hormone therapy. Menopause 18:5, 575-581
CrossRef15
Melissa E. Hogg, Vinit N. Varu, Ashley K. Vavra, Daniel A. Popowich, Monisha N. Banerjee, Janet Martinez, Qun Jiang, Joseph E. Saavedra, Larry K. Keefer, Melina R. Kibbe. (2011) Effect of nitric oxide on neointimal hyperplasia based on sex and hormone status. Free Radical Biology and Medicine 50:9, 1065-1074
CrossRef16
Christel Renoux, Samy Suissa. (2011) Hormone therapy administration in postmenopausal women and risk of stroke. Women's Health 7:3, 355-361
CrossRef17
Vassiliki Papagianni, Efthimios Deligeoroglou, Evangelos Makrakis, Dimitrios Botsis, George Creatsas. (2011) Response to hormonal treatment of young females with primary or very premature ovarian failure. Gynecological Endocrinology 27:5, 291-299
CrossRef18
E. S. Schernhammer, P. Razavi, T. Y. Li, A. A. Qureshi, J. Han. (2011) Rotating Night Shifts and Risk of Skin Cancer in the Nurses' Health Study. JNCI Journal of the National Cancer Institute 103:7, 602-606
CrossRef19
Sergi Soriano, Cristina Ripoll, Esther Fuentes, Alejandro Gonzalez, Paloma Alonso-Magdalena, Ana B. Ropero, Ivan Quesada, Angel Nadal. (2011) Regulation of KATP channel by 17β-estradiol in pancreatic β-cells. Steroids
CrossRef20
Eun Young Kim, In-Hee Baek, Mee Ra Rhyu. (2011) Cardioprotective effects of aqueous Schizandra chinensis fruit extract on ovariectomized and balloon-induced carotid artery injury rat models: Effects on serum lipid profiles and blood pressure. Journal of Ethnopharmacology 134:3, 668-675
CrossRef21
David R. Rubinow, Susan S. Girdler. (2011) Hormones, heart disease, and health: individualized medicine versus throwing the baby out with the bathwater. Depression and Anxiety 28:4, 282-296
CrossRef22
Pan-pan Zhen, Jin-hong Duan, Qian Zhao, Dan-dan Hou, Hong-xia Wang, Ni Hong, Hui-xian Zhen, Wen Wang. (2011) Phytoestrogen α-zearalanol improves vascular function in ovariectomized hyperhomocysteinemic rats. Atherosclerosis 215:2, 309-315
CrossRef23
Yoshiyuki Tohno, Setsuko Tohno, Pasuk Mahakkanukrauh, Takeshi Minami, Apichat Sinthubua, Patipath Suwannahoy, Nutcharin Ongkana, Sikrai Laowatthanaphong, Cho Azuma. (2011) Gender Difference in Accumulation of Calcium and Phosphorus in the Left Coronary Arteries of Thais. Biological Trace Element Research
CrossRef24
Midori Okumura, Masaru Iwai, Hirotomo Nakaoka, Hisako Sone, Harumi Kanno, Izumi Senba, Masaharu Ito, Masatsugu Horiuchi. (2011) Possible involvement of AT2 receptor dysfunction in age-related gender difference in vascular remodeling. Journal of the American Society of Hypertension 5:2, 76-84
CrossRef25
S. Mitchell Harman, Eric Vittinghoff, Eliot A. Brinton, Matthew J. Budoff, Marcelle I. Cedars, Rogerio A. Lobo, George R. Merriam, Virginia M. Miller, Frederick Naftolin, Lubna Pal, Nanette Santoro, Hugh S. Taylor, Dennis M. Black. (2011) Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes. The American Journal of Medicine 124:3, 199-205
CrossRef26
DINO A. GIUSSANI, ANDREW J. W. FLETCHER, DAVID S. GARDNER. (2011) Sex Differences in the Ovine Fetal Cortisol Response to Stress. Pediatric Research 69:2, 118-122
CrossRef27
Karin Schenck-Gustafsson, Mark Brincat, C. Tamer Erel, Marco Gambacciani, Irene Lambrinoudaki, Mette H. Moen, Florence Tremollieres, Svetlana Vujovic Serge Rozenberg, Margaret Rees. (2011) EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas 68:1, 94-97
CrossRef28
Xiaomei Meng, Xiangguo Dai, Tang-Dong Liao, Martin D'Ambrosio, Fangfei Wang, James J. Yang, Xiao-Ping Yang. (2011) Dose-dependent toxic effects of high-dose estrogen on renal and cardiac injury in surgically postmenopausal mice. Life Sciences 88:3-4, 178-186
CrossRef29
J. Christopher Gallagher, Jeffrey P. Levine. (2011) Preventing osteoporosis in symptomatic postmenopausal women. Menopause 18:1, 109-118
CrossRef30
Qiu-Li Zhang, Jens Baumert, Karl-Heinz Ladwig, H-Erich Wichmann, Christa Meisinger, Angela Döring. (2011) Association of daily tar and nicotine intake with incident myocardial infarction: Results from the population-based MONICA/KORA Augsburg Cohort Study 1984 - 2002. BMC Public Health 11:1, 273
CrossRef31
Amparo C. Villablanca, Muthuvel Jayachandran, Carole Banka. (2010) Atherosclerosis and sex hormones: current concepts. Clinical Science 119:12, 493-513
CrossRef32
Daisaku Yoshihara, Noriko Fujiwara, Keiichiro Suzuki. (2010) Antioxidants: Benefits and risks for long-term health. Maturitas 67:2, 103-107
CrossRef33
Andrea H. Tackett, Alison L. Bailey, Joanne Micale Foody, Julie M. Miller, Carolyn Apperson-Hansen, E. Magnus Ohman, Judith S. Hochman, Sharon L. Karnash, Robert M. Califf, Eric J. Topol, David J. Moliterno. (2010) Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: Insights from the GUSTO-III trial. American Heart Journal 160:4, 678-684
CrossRef34
C. J. Haines, E. Farrell. (2010) Menopause management: a cardiovascular risk-based approach. Climacteric 13:4, 328-339
CrossRef35
Krista F. Huybrechts, Ellen M. Mikkelsen, Tina Christensen, Anders H. Riis, Elizabeth E. Hatch, Lauren A. Wise, Henrik Toft Sørensen, Kenneth J. Rothman. (2010) A successful implementation of e-epidemiology: the Danish pregnancy planning study ‘Snart-Gravid’. European Journal of Epidemiology 25:5, 297-304
CrossRef36
Megan Krause, Thomas L. Wheeler, Holly E. Richter, Thomas E. Snyder. (2010) Systemic Effects of Vaginally Administered Estrogen Therapy. Female Pelvic Medicine & Reconstructive Surgery 16:3, 188-195
CrossRef37
Jeremy L. Herrmann, Aaron M. Abarbanell, Brent R. Weil, Mariuxi C. Manukyan, Jeffrey A. Poynter, Yue Wang, Arthur C. Coffey, Daniel R. Meldrum. (2010) Gender Dimorphisms in Progenitor and Stem Cell Function in Cardiovascular Disease. Journal of Cardiovascular Translational Research 3:2, 103-113
CrossRef38
Jan L. Shifren, Isaac Schiff. (2010) Role of Hormone Therapy in the Management of Menopause. Obstetrics & Gynecology 115:4, 839-855
CrossRef39
Toshio Hayashi, Akihisa Iguchi. (2010) Possibility of the regression of atherosclerosis through the prevention of endothelial senescence by the regulation of nitric oxide and free radical scavengers. Geriatrics & Gerontology International
CrossRef40
Xiaohong Jiang, Yan Zhang, Dongxia Hou, Lingyun Zhu, Wei Xu, Li Ding, Xiaoqiang Qi, Guoxun Sun, Chang Liu, Junfeng Zhang, Ke Zen, Yang Xiang, Chen-Yu Zhang. (2010) 17β-Estradiol inhibits oleic acid-induced rat VSMC Proliferation and migration by restoring PGC-1α expression. Molecular and Cellular Endocrinology 315:1-2, 74-80
CrossRef41
Katey Rayner, Yong-Xiang Chen, Tara Siebert, Edward R. O'Brien. (2010) Heat Shock Protein 27: Clue to Understanding Estrogen-Mediated Atheroprotection?. Trends in Cardiovascular Medicine 20:2, 53-57
CrossRef42
Pauliina Tuomikoski, Tomi S. Mikkola, Esa Hämäläinen, Matti J. Tikkanen, Ursula Turpeinen, Olavi Ylikorkala. (2010) Biochemical markers for cardiovascular disease in recently postmenopausal women with or without hot flashes. Menopause 17:1, 145-151
CrossRef43
Mahmoud M El-Mas, Abdel A Abdel-Rahman. (2009) Longitudinal assessment of the effects of oestrogen on blood pressure and cardiovascular autonomic activity in female rats. Clinical and Experimental Pharmacology and Physiology 36:10, 1002-1009
CrossRef44
Jae-Yen Song, Min-Joung Kim, Hyun-Hee Jo, Seong-Jin Hwang, Boah Chae, Jae-Eun Chung, Dong-Jin Kwon, Young-Ok Lew, Yong-Taik Lim, Jang-Heub Kim, Jin-Hong Kim, Mee-Ran Kim. (2009) Antioxidant effect of estrogen on bovine aortic endothelial cells. The Journal of Steroid Biochemistry and Molecular Biology 117:1-3, 74-80
CrossRef45
Amparo C. Villablanca, Amy Tenwolde, Michael Lee, Melissa Huck, Shannon Mumenthaler, John C. Rutledge. (2009) 17β-Estradiol Prevents Early-Stage Atherosclerosis in Estrogen Receptor-Alpha Deficient Female Mice. Journal of Cardiovascular Translational Research 2:3, 289-299
CrossRef46
Nanette Santoro, Janne Komi. (2009) Prevalence and Impact of Vaginal Symptoms among Postmenopausal Women. Journal of Sexual Medicine 6:8, 2133-2142
CrossRef47
Francesco Perticone, Angela Sciacqua, Raffaele Maio, Maria Perticone, Irma Laino, Rosamaria Bruni, Serena Di Cello, Giulia Galiano Leone, Laura Greco, Francesco Andreozzi, Giorgio Sesti. (2009) Renal function predicts cardiovascular outcomes in southern Italian postmenopausal women. European Journal of Cardiovascular Prevention & Rehabilitation 16:4, 481-486
CrossRef48
Leslie Spangler, Susan D. Reed, Larissa Nekhyludov, Louis C. Grothaus, Andrea Z. LaCroix, Katherine M. Newton. (2009) Provider attributes associated with hormone therapy prescribing frequency. Menopause 16:4, 810-816
CrossRef49
Y Ma, WT Cheng, S Wu, TM Wong. (2009) Oestrogen confers cardioprotection by suppressing Ca 2+ /calmodulin-dependent protein kinase II. British Journal of Pharmacology 157:5, 705-715
CrossRef50
Helena Chmura Kraemer. (2009) Events per person-time (incidence rate): A misleading statistic?. Statistics in Medicine 28:6, 1028-1039
CrossRef51
Bang-Hyun Kim, Young-Suk Won, Dae-Yong Kim, Bora Kim, Eun-Young Kim, Mi-Jung Yoon, Goo-Taeg Oh. (2009) Signal crosstalk between estrogen and peroxisome proliferator-activated receptor α on adiposity. BMB Reports 42:2, 91-95
CrossRef52
Sang-Han Lee, Hee Jeong Kim, Hyo Jin Kang, Yoon-Jin Lee, Hae-Seon Nam, Insoo Bae. (2009) Reactive Oxygen Species Generated by 17β-estradiol Play a Role in the Up-regulation of GPX4 Protein in MCF-7 Breast Cancer Cells. Journal of Breast Cancer 12:3, 134
CrossRef53
Ellen W. Seely, Steven Grinspoon. 2009. Patient-Oriented ResearchClinical Pathophysiology and Clinical Therapeutics. , 3-12.
CrossRef54
Toshio Hayashi, Kumiko Yano, Hisako Matsui-Hirai, Hiroki Yokoo, Yuichi Hattori, Akihisa Iguchi. (2008) Nitric oxide and endothelial cellular senescence. Pharmacology & Therapeutics 120:3, 333-339
CrossRef55
Guido Michels, Uta C. Hoppe. (2008) Rapid actions of androgens. Frontiers in Neuroendocrinology 29:2, 182-198
CrossRef56
William W. H. Ng, Wendy Keung, Yan Chun Xu, Kwok F. J. Ng, George P. H. Leung, Paul M. Vanhoutte, Patrick C. Choy, Ricky Y. K. Man. (2008) Genistein potentiates protein kinase A activity in porcine coronary artery. Molecular and Cellular Biochemistry 311:1-2, 37-44
CrossRef57
Cesar E. Fernandes, Luciano M. Pompei, Rogério B. Machado, José Arnaldo S. Ferreira, Nilson R. Melo, Sergio Peixoto. (2008) Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow. Maturitas 59:3, 249-258
CrossRef58
Richard E Hedrick. (2008) Low-dose estradiol gel 0.1% for the treatment of vasomotor symptoms associated with menopause. Expert Review of Obstetrics & Gynecology 3:2, 155-162
CrossRef59
A Satake, M Takaoka, M Nishikawa, M Yuba, Y Shibata, K Okumura, K Kitano, H Tsutsui, K Fujii, S Kobuchi, M Ohkita, Y Matsumura. (2008) Protective effect of 17β-estradiol on ischemic acute renal failure through the PI3K/Akt/eNOS pathway. Kidney International 73:3, 308-317
CrossRef60
X. Liu, H. Ogawa, R. Ando, T. Nakakuki, T. Kishida, K. Ebihara. (2007) Heat-Moisture Treatment of High-Amylose Corn Starch Increases Dietary Fiber Content and Lowers Plasma Cholesterol in Ovariectomized Rats. Journal of Food Science 72:9, S652-S658
CrossRef61
Francis Bayard, Simone Clamens, Georges Delsol, Nelly Blaes, Arlette Maret, Jean-Charles Faye. 2007. Oestrogen Synthesis, Oestrogen Metabolism and Functional Oestrogen Receptors in Bovine Aortic Endothelial Cells. , 122-138.
CrossRef62
M. R. Vickers, T. W. Meade, H. C. Wilkes. 2007. Hormone Replacement Therapy and Cardiovascular Disease: The Case for a Randomized Controlled Trial. , 150-170.
CrossRef63
Susan WS Leung, Hwee Teoh, Wendy Keung, Ricky YK Man. (2007) NON-GENOMIC VASCULAR ACTIONS OF FEMALE SEX HORMONES: PHYSIOLOGICAL IMPLICATIONS AND SIGNALLING PATHWAYS. Clinical and Experimental Pharmacology and Physiology 34:8, 822-826
CrossRef64
S. Asgary, J. Moshtaghian, G. Naderi, Z. Fatahi, M. Hosseini, G. Dashti, S. Adibi. (2007) Effects of dietary red clover on blood factors and cardiovascular fatty streak formation in hypercholesterolemic rabbits. Phytotherapy Research 21:8, 768-770
CrossRef65
Virginia M Miller, Muthuvel Jayachandran, Whyte G Owen. (2007) AGEING, OESTROGEN, PLATELETS AND THROMBOTIC RISK. Clinical and Experimental Pharmacology and Physiology 34:8, 814-821
CrossRef66
Ricky YK Man, Susan WS Leung. (2007) INTRODUCTION. Clinical and Experimental Pharmacology and Physiology 34:8, 799-800
CrossRef67
Kazuhiro Takahashi, Akiko Mori-Abe, Keiko Takata, Tsuyoshi Ohta, Jun Kawagoe, Seiji Tsutsumi, Masahide Ohmichi, Hirohisa Kurachi. (2007) Raloxifene improves the ovariectomy-induced impairment in endothelium-dependent vasodilation. Menopause 14:4, 656-661
CrossRef68
Thomas A. Wilson, Frank Orthoefer, Robert J. Nicolosi. (2007) Soy protein concentrate lowers serum high-density lipoprotein cholesterol concentrations compared with casein in ovariectomized rats fed a low-fat, cholesterol-free diet. Nutrition Research 27:7, 417-422
CrossRef69
Carlo Foresta, Daniela Zuccarello, Andrea Biagioli, Luca De Toni, Elisa Prana, Valentina Nicoletti, Guido Ambrosini, Alberto Ferlin. (2007) Oestrogen stimulates endothelial progenitor cells via oestrogen receptor-?. Clinical Endocrinology 0:0, 070615230707002-???
CrossRef70
Anton H van den Meiracker, Willem de Ronde. (2007) Gender differences in vascular disease: not a simple explanation. Journal of Hypertension 25:6, 1193-1194
CrossRef71
Yvan Touitou, Andre Bogdan. (2007) Circadian and seasonal variations of physiological and biochemical determinants of acute myocardial infarction. Biological Rhythm Research 38:3, 169-179
CrossRef72
Vipin V. Dhote, R. Balaraman. (2007) Gender specific effect of progesterone on myocardial ischemia/reperfusion injury in rats. Life Sciences 81:3, 188-197
CrossRef73
Roxana Campisi, Fernando D. Marengo. (2007) Cardiovascular Effects of Tibolone: A Selective Tissue Estrogenic Activity Regulator. Cardiovascular Drug Reviews 25:2, 132-145
CrossRef74
David F. Archer. (2007) Drospirenone, a progestin with added value for hypertensive postmenopausal women. Menopause 14:3, 352-354
CrossRef75
Hideaki Kawanishi, Youichi Hasegawa, Daisuke Nakano, Mamoru Ohkita, Masanori Takaoka, Yukihiro Ohno, Yasuo Matsumura. (2007) INVOLVEMENT OF THE ENDOTHELIN ETB RECEPTOR IN GENDER DIFFERENCES IN DEOXYCORTICOSTERONE ACETATE-SALT-INDUCED HYPERTENSION. Clinical and Experimental Pharmacology and Physiology 34:4, 280-285
CrossRef76
Liu Weimin, Cao Yujing, Li Jing, Hu Zeng, Zhao Ping, Duan Enkui. (2007) The expression of CD9 in the peri-implantation mouse uterus is upregulated in an ovarian steroid hormone–dependent manner. Fertility and Sterility 87:3, 664-670
CrossRef77
David F. Archer. (2007) Medical decisions regarding hormone therapy for menopausal women are significantly influenced by the media. Pharmacoepidemiology and Drug Safety 16:1, 28-31
CrossRef78
Stephanie Beer, M. Reincke, M. Kral, F. Callies, H. Strömer, C. Dienesch, S. Steinhauer, G. Ertl, B. Allolio, S. Neubauer. (2007) High-dose 17β–estradiol treatment prevents development of heart failure post–myocardial infarction in the rat. Basic Research in Cardiology 102:1, 9-18
CrossRef79
Marie-Pascale Guay, Alice Dragomir, Danielle Pilon, Yola Moride, Sylvie Perreault. (2007) Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiology and Drug Safety 16:1, 17-27
CrossRef80
Suman Sood, Steven Stein, Barbara A. Konkle. 2007. Thrombotic Risk of Contraceptives and Other Hormonal Therapies. , 567-580.
CrossRef81
Dennis K.Y. Yeung, Susan W.S. Leung, Yan Chun Xu, Paul M. Vanhoutte, Ricky Y.K. Man. (2006) Puerarin, an isoflavonoid derived from Radix puerariae, potentiates endothelium-independent relaxation via the cyclic AMP pathway in porcine coronary artery. European Journal of Pharmacology 552:1-3, 105-111
CrossRef82
Aleksandar Jovanović. (2006) Ageing, gender and cardiac sarcolemmal K ATP channels. Journal of Pharmacy and Pharmacology 58:12, 1585-1589
CrossRef83
Daisuke Kurumazuka, Tatsuhiko Mori, Noriko Matsumoto, Hisashi Shirakawa, Sayaka Kimura, Daisuke Nakano, Tetsuya Hayashi, Yasushi Kitaura, Yasuo Matsumura. (2006) Gender difference of atorvastatin's vasoprotective effect in balloon-injured rat carotid arteries. European Journal of Pharmacology 553:1-3, 263-268
CrossRef84
Namiko Yada-Hashimoto, Yukihiro Nishio, Masahide Ohmichi, Jun Hayakawa, Seiji Mabuchi, Koji Hisamoto, Yuki Nakatsuji, Hiroshi Sasaki, Hozumi Seino-Noda, Masahiro Sakata, Keiichi Tasaka, Yuji Murata. (2006) Estrogen and raloxifene inhibit the monocytic chemoattractant protein-1-induced migration of human monocytic cells via nongenomic estrogen receptor ??. Menopause 13:6, 935-941
CrossRef85
Alejandro Arana, Cristina Varas, Antonio Gonz??lez-P??rez, Lia Guti??rrez, Lars Bjerrum, Luis A. Garc??a Rodr??guez. (2006) Hormone therapy and cerebrovascular events. Menopause 13:5, 730-736
CrossRef86
Davide Serrano, Luigi Mariani, Serena Mora, Aliana Guerrieri-Gonzaga, Massimiliano Cazzaniga, Cristina Daldoss, Francesca Ramazzotto, Irene Feroce, Andrea Decensi, Bernardo Bonanni. (2006) Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT. Maturitas 55:1, 69-75
CrossRef87
Marianne Canonico, Céline Straczek, Emmanuel Oger, Geneviève Plu-Bureau, Pierre-Yves Scarabin. (2006) Postmenopausal hormone therapy and cardiovascular disease: An overview of main findings. Maturitas 54:4, 372-379
CrossRef88
Jacqueline E. Lewis, Leslie A. Nickell, Lilian U. Thompson, John P. Szalai, Alex Kiss, John R. Hilditch. (2006) A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause 13:4, 631-642
CrossRef89
Liu Ke-ju, Wang Wen-jun, Li Da-jin, Jin Hui-fang, Zhou Wen-jiang. (2006) Effect of Gengnianchun Recipe on bone mineral density, bone biomechanical parameters and serum lipid level in ovariectomized rats. Chinese Journal of Integrative Medicine 12:2, 132-136
CrossRef90
Xiong Liu, Taro Kishida, Kiyoshi Ebihara. (2006) High Amylose Cornstarch Decreases Plasma Triacylglycerol Concentration, but not Plasma Cholesterol, in a Dose-Dependent Manner. Journal of Food Science 71:5, S379-S384
CrossRef91
Mert Gol, Nezihi Baris, Sema Guneri, Cemal Posaci. (2006) The effect of raloxifene on cardiac autonomic regulation in osteoporotic women. American Journal of Obstetrics and Gynecology 194:5, 1249-1254
CrossRef92
Chi Ming Wong, Xiaoqiang Yao, Chak Leung Au, Suk Ying Tsang, Kwok Pui Fung, Ismail Laher, Paul M. Vanhoutte, Yu Huang. (2006) Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats. Vascular Pharmacology 44:5, 290-298
CrossRef93
George E. Christodoulakos, Irene V. Lambrinoudaki, Emmanuel V. Economou, Constantinos Papadias, Constantinos P. Panoulis, Evangelia E. Kouskouni, Sofia A. Vlachou, George C. Creatsas. (2006) Differential Effect of Hormone Therapy and Tibolone on Lipids, Lipoproteins, and the Atherogenic Index of Plasma. Journal of Cardiovascular Pharmacology 47:4, 542-548
CrossRef94
Anne Morise, Jacques Mourot, Carole Boué, Nicole Combe, Ghislaine Amsler, Daniel Gripois, Annie Quignard-Boulangé, Laurent Yvan-Charvet, Evelyne Fénart, Pierre Weill, Dominique Hermier. (2006) Gender-related response of lipid metabolism to dietary fatty acids in the hamster. British Journal of Nutrition 95:04, 709
CrossRef95
M. Khazaei, M. Nematbakhsh. (2006) Serum level of vascular endothelial growth factor is increased by estrogen replacement therapy in normotensive and DOCA–Salt hypertensive ovariectomized rats. Clinica Chimica Acta 365:1-2, 206-210
CrossRef96
Louise Thunell, Björn Andersson, Marie Glassell, Lars-Åke Mattsson. (2006) The effect of continuous combined HRT on glucose homeostasis and plasma lipids. Maturitas 53:4, 430-438
CrossRef97
Bruce R. Carr, Naveed Khan, Beverley Adams-Huet, Nirupama Kakarla, Jon C. Havelock, Jennifer Gell. (2006) Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women. Fertility and Sterility 85:3, 667-673
CrossRef98
H. Sumino, S. Ichikawa, T. Takahashi, H. Sakamoto, K. Goto-Onozato, S. Koya, T. Kanda, M. Nara, K. Seki, M. Murakami, M. Kurabayashi. (2006) Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women. Maturitas 53:3, 306-314
CrossRef99
Mert Gol, Pinar Akan, Erbil Dogan, Cigdem Karas, Ugur Saygili, Cemal Posaci. (2006) Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 53:3, 252-259
CrossRef100
M. Birkhäuser. (2006) Klinische Bedeutung von gestagenen Partialwirkungen. Gynäkologische Endokrinologie 4:1, 52-64
CrossRef101
Gulay Kurtay, Batuhan Ozmen, Imge Erguder. (2006) A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women. Maturitas 53:1, 32-38
CrossRef102
E. Løkkegaard, Z. Jovanovic, B.L. Heitmann, N. Keiding, B. Ottesen, A.T. Pedersen. (2006) The association between early menopause and risk of ischaemic heart disease: Influence of Hormone Therapy. Maturitas 53:2, 226-233
CrossRef103
Pelin Batur, Carol E. Blixen, Halle C.F. Moore, Holly L. Thacker, Meng Xu. (2006) Menopausal hormone therapy (HT) in patients with breast cancer. Maturitas 53:2, 123-132
CrossRef104
Shinji Fukuhara, Shonosuke Matsushita, Yuzuru Sakakibara. (2006) Changes in Coronary Resistance Related to the Stages of the Female Life Cycle. Circulation Journal 70:4, 478-481
CrossRef105
Dianna J Magliano, Sophie L Rogers, Michael J Abramson, Andrew M Tonkin. (2006) Systematic review: Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology 113:1, 5-14
CrossRef106
Tatjana El??ne Vogelvang, Marius Jan van der Mooren, Velja Mijatovic, Peter Kenemans. (2006) Emerging Selective Estrogen Receptor Modulators. Drugs 66:2, 191-221
CrossRef107
Edward L. Klaiber, William Vogel, Susan Rako. (2005) A critique of the Women’s Health Initiative hormone therapy study. Fertility and Sterility 84:6, 1589-1601
CrossRef108
Juliet Compston. (2005) How to manage osteoporosis after the menopause. Best Practice & Research Clinical Rheumatology 19:6, 1007-1019
CrossRef109
Miguel A. Hernán, James M. Robins, Luis A. García Rodríguez. (2005) Discussion on "Statistical Issues Arising in the Women's Health Initiative". Biometrics 61:4, 922-930
CrossRef110
G. Creatsas, G. Christodoulakos, I. Lambrinoudaki. (2005) Cardiovascular disease: Screening and management of the a-symptomatic high-risk post-menopausal woman. Maturitas 52, 32-37
CrossRef111
Nancy Kim, Cary Gross, Jeptha Curtis, Glen Stettin, Stephen Wogen, Nami Choe, Harlan M. Krumholz. (2005) The Impact of Clinical Trials on the Use of Hormone Replacement Therapy. A Population-Based Study. Journal of General Internal Medicine 20:11, 1026-1031
CrossRef112
Lital Keinan-Boker, Rita Dictiar, Noga Garty, Manfred S. Green. (2005) Prevalence and correlates of hormonal therapy among Israeli women in the post-WHI era. Maturitas 52:3-4, 364-373
CrossRef113
R. Salguero Bodes, I. Sánchez Pérez, R. Matía Francés, C. Sáenz de la Calzada Campos. (2005) Cardiopatía isquémica. Concepto. Aspectos epidemiológicos. Etiopatogenia. Clasificación biológica y clínica. Implicaciones en la calidad de vida. Medicine - Programa de Formación Médica Continuada Acreditado 9:39, 2571-2579
CrossRef114
Rika Egami, Yoshihiro Tanaka, Masahiro Nozaki, Keiko Koera, Akiko Okuma, Hitoo Nakano. (2005) Chronic treatment with 17β-estradiol increases susceptibility of smooth muscle cells to nitric oxide. European Journal of Pharmacology 520:1-3, 142-149
CrossRef115
R. Salguero Bodes, I. Sánchez Pérez, C. Pindado Rodríguez, C. Sáenz de la Calzada Campos. (2005) Tratamiento del ángor. Criterios de respuesta. Seguimiento de la respuesta. Medicine - Programa de Formación Médica Continuada Acreditado 9:39, 2606-2614
CrossRef116
William Insull, Michael H. Davidson, Pandurang M. Kulkarni, Suresh Siddhanti, Angelina V. Ciaccia, Cheryl A. Keech. (2005) Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metabolism 54:7, 939-946
CrossRef117
Sharon J Rolnick, Richard A Kopher, Terese A DeFor, Mary E Kelley. (2005) Hormone use and patient concerns after the findings of the Women??s Health Initiative. Menopause 12:4, 399-404
CrossRef118
Ulla Pripp, Margita Eriksson-Berg, Kristina Orth-Gomér, Karin Schenck-Gustafsson, Britt-Marie Landgren. (2005) Does body mass index, smoking, lipoprotein levels, surgically induced menopause, hormone replacement therapy, years since menopause, or age affect hemostasis in postmenopausal women?. Gender Medicine 2:2, 88-95
CrossRef119
Juuso Mäkinen, Mikko J. Järvisalo, Pasi Pöllänen, Antti Perheentupa, Kerttu Irjala, Markku Koskenvuo, Juha Mäkinen, Ilpo Huhtaniemi, Olli T. Raitakari. (2005) Increased Carotid Atherosclerosis in Andropausal Middle-Aged Men. Journal of the American College of Cardiology 45:10, 1603-1608
CrossRef120
Louise Thunell, Elisabeth Stadberg, Ian Milsom, Lars-Ake Mattsson. (2005) Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval. Acta Obstetricia et Gynecologica Scandinavica 84:4, 395-401
CrossRef121
Marie-Luise Gross, Eberhard Ritz, Michael Korsch, Marcin Adamczak, Monika Weckbach, Gerhard Mall, Irina Berger, Alexander Hansen, Kerstin Amann. (2005) Effects of estrogens on cardiovascular structure in uninephrectomized SHRsp rats. Kidney International 67:3, 849-857
CrossRef122
Susana Bassol, Sebastian Carranza-Lira, Cuauhtemoc Celis-Gonzalez, Samuel Santoyo, Alfonso Murillo, Norma Martinez, Javier Santos, Victoriano Llaca, Fernanda Rio de la Loza, Jesus Zarain, Angela Maggio da Fonseca, Aroldo F. Camargos, Edmund C. Baracat, Marcos F.da Sá, Juana Bayo, Liliana Adaro, Carlos Gurucharri, Martha Murga, Nestor Siseles, Fabiana Sayegh, Antonio Tempone, Luis M. Tempone, Roberto I. Tozzini, Roberto Boccanera, Carlos Naranjo, Fabio Sanchez, Gustavo Gomez, Stella Blanco, Roberto Reyes-Marquez, Gerhard Albrecht, Pedro Cano Rios. (2005) The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women. Maturitas 50:3, 189-195
CrossRef123
Yasuhiro Nakamura, Takashi Suzuki, Hironobu Sasano. (2005) Estrogen actions and in situ synthesis in human vascular smooth muscle cells and their correlation with atherosclerosis. The Journal of Steroid Biochemistry and Molecular Biology 93:2-5, 263-268
CrossRef124
Wendy Keung, Paul M Vanhoutte, Ricky Y K Man. (2005) Acute impairment of contractile responses by 17β-estradiol is cAMP and protein kinase G dependent in vascular smooth muscle cells of the porcine coronary arteries. British Journal of Pharmacology 144:1, 71-79
CrossRef125
Satoshi Nawate, Mitsuhiro Fukao, Ichiro Sakuma, Takamitsu Soma, Kazuhiko Nagai, Osamu Takikawa, Soichi Miwa, Akira Kitabatake. (2005) Reciprocal changes in endothelium-derived hyperpolarizing factor- and nitric oxide-system in the mesenteric artery of adult female rats following ovariectomy. British Journal of Pharmacology 144:2, 178-189
CrossRef126
Alessandra Crisafulli, Domenica Altavilla, Herbert Marini, Alessandra Bitto, Domenico Cucinotta, Nicola Frisina, Francesco Corrado, Rosario D'Anna, Giovanni Squadrito, Elena B. Adamo, Rolando Marini, Adolfo Romeo, Francesco Cancellieri, Michele Buemi, Francesco Squadrito. (2005) Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause 12:2, 186-192
CrossRef127
ENEY O. FERNANDES, RUY S. MORAES, ELTON L. FERLIN, MARIA CELESTE O. WENDER, JORGE P. RIBEIRO. (2005) Hormone Replacement Therapy Does Not Affect the 24-Hour Heart Rate Variability in Postmenopausal Women:. Results of a Randomized, Placebo-Controlled Trial with Two Regimens. Pacing and Clinical Electrophysiology 28:s1, S172-S177
CrossRef128
Francisco Rosa, Rafael Antequera, José Vásquez, Eduardo Romero-Vecchione, Angela Martínez. (2005) Testosterone and Nandrolone Sensitization of Brain Anteroventral Area of Third Ventricle to Hypertonic NaCl-Induced Sympathetic Response. Pharmacology 75:1, 5-12
CrossRef129
Yoshihiko Yamanaka, Hiroya Matsuo, Osamu Kurachi, Noriyoshi Oki, Satoshi Nakago, Kyousuke Takeuchi, Takeshi Maruo. (2005) Effects of Combined Estriol/Pravastatin Therapy on Intima-Media Thickness of Common Carotid Artery in Hyperlipidemic Postmenopausal Women. Gynecologic and Obstetric Investigation 59:2, 67-69
CrossRef130
Barbara P. Yawn, Peter C. Wollan, Steven J. Jacobsen, George E. Fryer, Veronique L. Roger. (2004) Identification of Women's Coronary Heart Disease and Risk Factors Prior to First Myocardial Infarction. Journal of Women's Health 13:10, 1087-1100
CrossRef131
Yasuhiro Nakamura, Katsuhide Igarashi, Takashi Suzuki, Jun Kanno, Tohru Inoue, Chika Tazawa, Masayuki Saruta, Tomoko Ando, Noriko Moriyama, Toru Furukawa, Masao Ono, Takuya Moriya, Kiyoshi Ito, Haruo Saito, Tadashi Ishibashi, Shoki Takahashi, Shogo Yamada, Hironobu Sasano. (2004) E4F1, a Novel Estrogen-Responsive Gene in Possible Atheroprotection, Revealed by Microarray Analysis. The American Journal of Pathology 165:6, 2019-2031
CrossRef132
S. C. Halligan, B. Murtagh, R. J. Lennon, G. M. Pumper, V. Mathew, S. T. Higano, A. Lerman. (2004) Effect of Long-term Hormone Replacement Therapy on Coronary Endothelial Function in Postmenopausal Women. Mayo Clinic Proceedings 79:12, 1514-1520
CrossRef133
Akira Oishi, Masahide Ohmichi, Kazuhiro Takahashi, Toshifumi Takahashi, Akiko Mori-Abe, Jun Kawagoe, Reiko Otsu, Yoshiko Mochizuki, Noriyuki Inaba, Hirohisa Kurachi. (2004) Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells. Biochemical and Biophysical Research Communications 324:1, 193-198
CrossRef134
Weifei Zhu, William V Everson, Eric J Smart. (2004) Estrogen in cardiovascular disease. Current Opinion in Lipidology 15:5, 589-593
CrossRef135
Alice Lai Shan Au, Ching Chi Kwok, Allen Ting Chun Lee, Yiu Wa Kwan, Macey Mei Sze Lee, Rong-Zhen Zhang, Sai Ming Ngai, Simon Ming Yuen Lee, Guo-Wei He, Kwok Pui Fung. (2004) Activation of iberiotoxin-sensitive, Ca2+-activated K+ channels of porcine isolated left anterior descending coronary artery by diosgenin. European Journal of Pharmacology 502:1-2, 123-133
CrossRef136
Kazuhiro Takahashi, Eiichi Tanaka, Maki Murakami, Akiko Mori-Abe, Jun Kawagoe, Keiko Takata, Masahide Ohmichi, Hirohisa Kurachi. (2004) Long-term hormone replacement therapy delays the age related progression of carotid intima-media thickness in healthy postmenopausal women. Maturitas 49:2, 170-177
CrossRef137
&NA;. (2004) Coronary Heart Disease. Obstetrics & Gynecology 104:Supplement, 41S-48S
CrossRef138
Sirpa-Liisa Hovi, Tiina Karttunen, Helle Karro, Elina Hemminki. (2004) Comparison of Estonian and Finnish physicians’ opinions of menopause and hormone therapy. Maturitas 49:2, 107-113
CrossRef139
Dipak K. Das. (2004) Sexual dimorphism and in the aging heart: role of estrogen, nitric oxide and beyond. Journal of Molecular and Cellular Cardiology 37:3, 667-669
CrossRef140
Kenan Saglam. (2004) Insulin Resistance and Postmenopausal Hormone Replacement Therapy. Metabolic Syndrome and Related Disorders 2:4, 234-240
CrossRef141
Zhong Dai, Hui-Qing Zhu, De-Jian Jiang, Jun-Ling Jiang, Han-Wu Deng, Yuan-Jian Li. (2004) 17β-Estradiol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. International Journal of Cardiology 96:2, 223-227
CrossRef142
Brigitte L. Sicat. (2004) Should Postmenopausal Hormone Therapy Be Used to Prevent Osteoporosis?. The Consultant Pharmacist 19:8, 725-735
CrossRef143
Carla Makhlouf Obermeyer, Robert F. Reynolds, Kim Price, Annie Abraham. (2004) Therapeutic decisions for menopause: results of the DAMES project in central Massachusetts. Menopause 11:4, 456-465
CrossRef144
Roxana N. Peroni, Marı́a L. Orliac, Damasia Becu-Villalobos, Juan P. Huidobro-Toro, Edda Adler-Graschinsky, Stella M. Celuch. (2004) Sex-linked differences in the vasorelaxant effects of anandamide in vascular mesenteric beds: role of oestrogens. European Journal of Pharmacology 493:1-3, 151-160
CrossRef145
Julia E Ostberg, Tatjana Damjanovic, Nada Dimkovic, Dominic Byrne, Dimitri P Mikhailidis, Gordana M Prelevic. (2004) Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. Fertility and Sterility 81:6, 1624-1631
CrossRef146
Frederick Naftolin, Hugh S. Taylor, Richard Karas, Eliot Brinton, Isadore Newman, Thomas B. Clarkson, Michael Mendelsohn, Rogerio A. Lobo, Debra R. Judelson, Lila E. Nachtigall, Christopher B. Heward, Harvey Hecht, Michael R. Jaff, S.Mitchell Harman. (2004) The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertility and Sterility 81:6, 1498-1501
CrossRef147
M Nematbakhsh, M Khazaei. (2004) The effect of estrogen on serum nitric oxide concentrations in normotensive and DOCA Salt hypertensive ovariectomized rats. Clinica Chimica Acta 344:1-2, 53-57
CrossRef148
Gideon Kopernik, Zeev Shoham. (2004) Tools for making correct decisions regarding hormone therapy. Part II. organ response and clinical applications. Fertility and Sterility 81:6, 1458-1477
CrossRef149
Thierry Chataigneau, Murielle Zerr, Marta Chataigneau, Fréanderic Hudlett, Carole Hirn, Fanny Pernot, Valéric Barbara Schini-Kerth. (2004) Chronic treatment with progesterone but not medroxyprogesterone acetate restores the endothelial control of vascular tone in the mesenteric artery of ovariectomized rats. Menopause 11:3, 255-263
CrossRef150
Radhika Nandur, Kavita Kumar, Amparo C. Villablanca. (2004) Cardiovascular Actions of Selective Estrogen Receptor Modulators and Phytoestrogens. Preventive Cardiology 7:2, 73-79
CrossRef151
Yasuhiro Nakamura, Takashi Suzuki, Yasuhiro Miki, Chika Tazawa, Kumiko Senzaki, Takuya Moriya, Haruo Saito, Tadashi Ishibashi, Shoki Takahashi, Shogo Yamada, Hironobu Sasano. (2004) Estrogen receptors in atherosclerotic human aorta: inhibition of human vascular smooth muscle cell proliferation by estrogens. Molecular and Cellular Endocrinology 219:1-2, 17-26
CrossRef152
Abdul Faraj, Thava Vasanthan. (2004) Soybean Isoflavones: Effects of Processing and Health Benefits. Food Reviews International 20:1, 51-75
CrossRef153
Karen Pazol, Jay R. Kaplan, David Abbott, Susan E. Appt, Mark E. Wilson. (2004) Practical measurement of total and bioavailable estradiol in female macaques. Clinica Chimica Acta 340:1-2, 117-126
CrossRef154
A. R. Scott, P. Dhindsa, J. Forsyth, P. Mansell. (2004) Effect of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with diabetes*. Diabetes, Obesity and Metabolism 6:1, 16-22
CrossRef155
Priscilla G. Masse, Juliana Dosy, D.E.C. Cole, J. Evroski, Jacques Allard, Michel D’Astous. (2004) Is Serum Ferritin an Additional Cardiovascular Risk Factor for All Postmenopausal Women?. Annals of Nutrition and Metabolism 48:6, 381-389
CrossRef156
Daniela Pochmann, Bárbara Rücker, Ana M.O. Battastini, João J.F. Sarkis. (2004) Ovariectomy and estradiol replacement therapy alters the adenine nucleotide hydrolysis in rat blood serum. Thrombosis Research 114:4, 275-281
CrossRef157
Anne Bloch Thomsen, Sandra Silvestri, Jens Haarbo, Claus Christiansen, Nina H. Bjarnason. (2004) Associated response in bone and lipids during hormone replacement therapy. Maturitas 47:1, 39-45
CrossRef158
NORIHIRO SUGINO. (2004) Yamaguchi Medical Journal 53:6, 261-264
CrossRef159
Crystal Whitney, Darren E R Warburton, Jiri Frohlich, Sammy Y Chan, Heather McKay, Karim Khan. (2004) Are Cardiovascular Disease and Osteoporosis Directly Linked?. Sports Medicine 34:12, 779-807
CrossRef160
Jane Morley Kotchen, Theodore A. Kotchen. (2003) Impact of female hormones on blood pressure: Review of potential mechanisms and clinical studies. Current Hypertension Reports 5:6, 505-512
CrossRef161
Nor Afiah MOHD ZULKEFLI, Sherina MOHD SIDIK. (2003) Prevalence of menopausal symptoms among female teachers in Seremban, Negeri Sembilan. Asia Pacific Family Medicine 2:4, 235-238
CrossRef162
Ebru Toker, Ozlem Yenice, Ihsan Akpinar, Erkin Aribal, Haluk Kazokoglu. (2003) The influence of sex hormones on ocular blood flow in women. Acta Ophthalmologica Scandinavica 81:6, 617-624
CrossRef163
Paula S. Derry. (2003) Why Do Professionals Disagree? The Case of Hormone Replacement Therapy and Coronary Heart Disease Prevention. Women & Health 38:3, 3-18
CrossRef164
Thomas B Clarkson, Susan E Appt. (2003) MPA and postmenopausal coronary artery atherosclerosis revisited. Steroids 68:10-13, 941-951
CrossRef165
Yasuhiro Nakamura, Yasuhiro Miki, Takashi Suzuki, Taisuke Nakata, Andrew David Darnel, Takuya Moriya, Chika Tazawa, Haruo Saito, Tadashi Ishibashi, Shoki Takahashi, Shogo Yamada, Hironobu Sasano. (2003) Steroid Sulfatase and Estrogen Sulfotransferase in the Atherosclerotic Human Aorta. The American Journal of Pathology 163:4, 1329-1339
CrossRef166
Esben Strodl, Justin Kenardy, Con Aroney. (2003) Perceived stress as a predictor of the self-reported new diagnosis of symptomatic CHD In older women. International Journal of Behavioral Medicine 10:3, 205-220
CrossRef167
Patcharin Tep-areenan, David A. Kendall, Michael D. Randall. (2003) Mechanisms of vasorelaxation to 17β-oestradiol in rat arteries. European Journal of Pharmacology 476:1-2, 139-149
CrossRef168
Omer L. Shedd, Marian C. Limacher. (2003) Prevention of cardiovascular disease in women. Current Treatment Options in Cardiovascular Medicine 5:4, 287-298
CrossRef169
Sayaka Miura, Eiichi Tanaka, Akiko Mori, Mayumi Toya, Kazuhiro Takahashi, Kenji Nakahara, Masahide Ohmichi, Hirohisa Kurachi. (2003) Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women. Maturitas 45:4, 293-298
CrossRef170
Claire L Curl, Igor R Wendt, Benedict J Canny, George Kotsanas. (2003) Effects of ovariectomy and 17beta-oestradiol replacement on [Ca2+]i in female rat cardiac myocytes. Clinical and Experimental Pharmacology and Physiology 30:7, 489-494
CrossRef171
Tamao Unemoto, Hideo Honda, Hiroshi Kogo. (2003) Differences in the mechanisms for relaxation of aorta induced by 17β-estradiol or progesterone between normotensive and hypertensive rats. European Journal of Pharmacology 472:1-2, 119-126
CrossRef172
Marie-Louise Lydrup, Marten Ferno. (2003) Correlation between estrogen receptor alpha expression, collagen content and stiffness in human uterine arteries. Acta Obstetricia et Gynecologica Scandinavica 82:7, 610-615
CrossRef173
C.J. Malkin. (2003) Testosterone for secondary prevention in men with ischaemic heart disease?. QJM 96:7, 521-529
CrossRef174
Baojian Xue, Meredith Hay. (2003) 17β-Estradiol inhibits excitatory amino acid-induced activity of neurons of the nucleus tractus solitarius. Brain Research 976:1, 41-52
CrossRef175
Joan M. Neuner, Ellen P. McCarthy, Roger B. Davis, Russell S. Phillips. (2003) Physician Counseling on Hormone Replacement Therapy and Bone Loss: Do Socioeconomic and Racial Characteristics of Women Influence Counseling?. Journal of Women's Health 12:5, 495-504
CrossRef176
Angelo Scuteri, Luigi Ferrucci. (2003) Blood Pressure, Arterial Function, Structure, and Aging: The Role of Hormonal Replacement Therapy in Postmenopausal Women. The Journal of Clinical Hypertension 5:3, 219-225
CrossRef177
Mitsuhiro Sanada, Yukihito Higashi, Keigo Nakagawa, Ichiro Kodama, Mikio Tsuda, Nobutaka Nagai, Kazuaki Chayama, Koso Ohama. (2003) Comparison of forearm endothelial function between premenopausal and postmenopausal women with or without hypercholesterolemia. Maturitas 44:4, 307-315
CrossRef178
Graziano Ceresini, Lorenzo Marchini, Isabella Rebecchi, Simonetta Morganti, Luca Bertone, Ilaria Montanari, Alberto Bacchi-Modena, Maria Sgarabotto, Monica Baldini, Licia Denti, Fabrizio Ablondi, Gian Paolo Ceda, Giorgio Valenti. (2003) Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women. Atherosclerosis 167:1, 121-127
CrossRef179
Sunil V. Rao, Robert M. Califf. (2003) Lessons Learned From Clinical Trials A Roundtable Discussion. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2:1, 55-59
CrossRef180
Sonia Davison, Susan R. Davis. (2003) Hormone replacement therapy: current controversies. Clinical Endocrinology 58:3, 249-261
CrossRef181
Masahide Ohmichi, Yuki Kanda, Koji Hisamoto, Ken-ichiro Morishige, Kazuhiro Takahashi, Kenjiro Sawada, Ryoko Minekawa, Keiichi Tasaka, Yuji Murata. (2003) Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas 44:2, 125-131
CrossRef182
HIROYUKI SUMINO, SHUICHI ICHIKAWA, MASAMI MURAKAMI, TETSUYA NAKAMURA, TSUGIYASU KANDA, TETSUO SAKAMAKI, HIDEKI MIZUNUMA, MASAHIKO KURABAYASHI. (2003) Effects of Hormone Replacement Therapy on Circulating Docosahexaenoic Acid and Eicosapentaenoic Acid Levels in Postmenopausal Women.. Endocrine Journal 50:1, 51-59
CrossRef183
Janell Thompson, Raouf A Khalil. (2003) Gender differences in the regulation of vascular tone. Clinical and Experimental Pharmacology and Physiology 30:1-2, 1-15
CrossRef184
Hiroki Momoi, Fumitaka Ikomi, Toshio Ohhashi. (2003) Estrogen-Induced Augmentation of Endothelium-Dependent Nitric Oxide-Mediated Vasodilation in Isolated Rat Cerebral Small Arteries.. The Japanese Journal of Physiology 53:3, 193-203
CrossRef185
Masahiko Igarashi, Akihiko Hirata, Toshiyuki Yamauchi, Hiroshi Yamaguchi, Hiromi Tsuchiya, Hiroshi Ohnuma, Yumi Jimbu, Yoko Okuyama, Toru Shirata, Nobuhiro Otsu, Haru Fukuyama, Sachiko Takahashi, Makoto Tominaga, Takeo Kato. (2003) Clinical Utility and Approach to Estimate Postprandial Hypertriglycemia by A Newly Designed Oral Fat-loading Test. Journal of Atherosclerosis and Thrombosis 10:5, 314-320
CrossRef186
Tommi A Koivu, Yue-Mei Fan, Kari M Mattila, Prasun Dastidar, Hannu Jokela, Seppo T Nikkari, Tarja Kunnas, Reijo Punnonen, Terho Lehtimäki. (2003) The effect of hormone replacement therapy on atherosclerotic severity in relation to ESR1 genotype in postmenopausal women. Maturitas 44:1, 29-38
CrossRef187
LeRoy E Rabbani, Nicole A Seminario, Robert R Sciacca, Hong Jun Chen, Elsa-Grace V Giardina. (2002) Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women. Journal of the American College of Cardiology 40:11, 1991-1999
CrossRef188
Kazushi Tsuda, Yukiko Kinoshita-Shimamoto, Keizo Kimura, Ichiro Nishio. (2002) Effect of oestrone on membrane fluidity of erythrocytes is mediated by a nitric oxide-dependent pathway: An electron paramagnetic resonance study. Clinical and Experimental Pharmacology and Physiology 29:11, 972-979
CrossRef189
Cosimo Massafra, Dino Gioia, Claudio De Felice, Michela Muscettola, Mariangela Longini, Giuseppe Buonocore. (2002) Gender-related differences in erythrocyte glutathione peroxidase activity in healthy subjects. Clinical Endocrinology 57:5, 663-667
CrossRef190
Enrique Teran, Carlos Escudero, Sandra Vivero. (2002) Physiological changes in platelet aggregation and nitric oxide levels during menstrual cycle in healthy women. Nitric Oxide 7:3, 217-220
CrossRef191
Hisakazu Ogita, Koichi Node, Hiroshi Asanuma, Shoji Sanada, Yulin Liao, Seiji Takashima, Masanori Asakura, Hidezo Mori, Yoshiro Shinozaki, Masatsugu Hori, Masafumi Kitakaze. (2002) Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. Journal of the American College of Cardiology 40:5, 998-1005
CrossRef192
Ettore Cicinelli, Louis J Ignarro, Pietro Galantino, Vincenzo Pinto, Bruno Barba, Sergio Schonauer. (2002) Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertility and Sterility 78:3, 464-468
CrossRef193
Stephanie Beer, Martin Reincke, Maike Kral, Su Zan Lie, Sonja Steinhauer, Harald H. H. W. Schmidt, Bruno Allolio, Stefan Neubauer. (2002) Susceptibility to Cardiac Ischemia/Reperfusion Injury Is Modulated by Chronic Estrogen Status. Journal of Cardiovascular Pharmacology 40:3, 420-428
CrossRef194
Virginia Massheimer, Nélida Polini, Cristina Alvarez, Silivia Benozzi, Juana Selles. (2002) 17β-Estradiol rapid stimulation of rat aorta NOS activity is prevented by oestrogen deficiency. Maturitas 43:1, 55-64
CrossRef195
J WAGNER. (2002) Reproductive hormones and cardiovascular disease*1Mechanism of action and clinical implications. Obstetrics and Gynecology Clinics of North America 29:3, 475-493
CrossRef196
Francesco Squadrito, Domenica Altavilla, Nunziata Morabito, Alessandra Crisafulli, Rosario D'Anna, Francesco Corrado, Pietro Ruggeri, Giuseppe M. Campo, Gioacchino Calapai, Achille P. Caputi, Giovanni Squadrito. (2002) The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis 163:2, 339-347
CrossRef197
Hiroshi Tatsumi, Jo Kitawaki, Kazunori Tanaka, Tetsuya Hosoda, Hideo Honjo. (2002) Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins. Maturitas 42:4, 287-294
CrossRef198
Hanny E Brussaard, Jan A Gevers Leuven, H.Michiel J Krans, Cornelis Kluft. (2002) The effect of 17β-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus. Vascular Pharmacology 39:3, 141-147
CrossRef199
Shehzad Basaria, Tam Nguyen, Robert S. Rosenson, Adrian S. Dobs. (2002) Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clinical Endocrinology 57:2, 209-214
CrossRef200
Harri J Ranki, Grant R Budas, Russell M Crawford, Anthony M Davies, Aleksandar Jovanović. (2002) 17β-Estradiol regulates expression of KATP channels in heart-derived H9c2 cells. Journal of the American College of Cardiology 40:2, 367-374
CrossRef201
Henny M.J. van Schrojenstein Lantman-de Valk, Nicole Schupf, Kristiina Patja. 2002. Reproductive and Physical Health. , 22-40.
CrossRef202
Daphne J. Theodorou, Stavroula J. Theodorou, David J. Sartoris. (2002) Treatment of osteoporosis: Current status and recent advances. Comprehensive Therapy 28:2, 109-122
CrossRef203
MARIA C. CID, H. WILLIAM SCHNAPER, HYNDA K. KLEINMAN. (2002) Estrogens and the Vascular Endothelium. Annals of the New York Academy of Sciences 966:1, 143-157
CrossRef204
Lauro Figueroa-Valverde, Hector Luna, Carlos Castillo-Henkel, Olga Muñoz-Garcia, Tomas Morato-Cartagena, Guillermo Ceballos-Reyes. (2002) Synthesis and evaluation of the cardiovascular effects of two, membrane impermeant, macromolecular complexes of dextran-testosterone. Steroids 67:7, 611-619
CrossRef205
K.Todd Piercy, Robert L. Donnell, Stacy S. Kirkpatrick, Carlos H. Timaran, Scott L. Stevens, Michael B. Freeman, Mitchell H. Goldman. (2002) Effects of Estrogen, Progesterone, and Combination Exposure on Interleukin-1β-Induced Expression of VCAM-1, ICAM-1, PECAM, and E-Selectin by Human Female Iliac Artery Endothelial Cells. Journal of Surgical Research 105:2, 215-219
CrossRef206
G Gorodeski. (2002) Update on cardiovascular disease in post-menopausal women. Best Practice & Research Clinical Obstetrics & Gynaecology 16:3, 329-355
CrossRef207
Ioannis Kallikazaros, Costas Tsioufis, Panagiotis Zambaras, Christodoulos Stefanadis, Pavlos Toutouzas. (2002) Conjugated estrogen administration improves common carotid artery elastic properties in normotensive postmenopausal women. Clinical Cardiology 25:4, 167-172
CrossRef208
Elizabeth A. Sparks, Lorraine Q. Frazier. (2002) Heritable Cardiovascular Disease in Women. Journal of Obstetric, Gynecologic, <html_ent glyph="@amp;" ascii="&"/> Neonatal Nursing 31:2, 217-228
CrossRef209
Thomas von Holst, Birgitt Salbach. (2002) Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women. Maturitas 41:3, 231-242
CrossRef210
Anne Peters Harmel. (2002) Considerations for treating dyslipidemia in special diabetic populations. Diabetes/Metabolism Research and Reviews 18:2, 88-95
CrossRef211
Shinichi Usui, Kazuhiro Suzuki, Hidetoshi Yamanaka, Takamitsu Nakano, Katsuyuki Nakajima, Yukichi Hara, Mitsuyo Okazaki. (2002) Estrogen treatment of prostate cancer increases triglycerides in lipoproteins as demonstrated by HPLC and immunoseparation techniques. Clinica Chimica Acta 317:1-2, 133-143
CrossRef212
Tsung-Ming Lee, Sheng-Fang Su, Tsai-Fwu Chou, Chang-Her Tsai. (2002) Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty. Journal of the American College of Cardiology 39:5, 871-877
CrossRef213
Gabor M Rubanyi, Anthony Johns, Katalin Kauser. (2002) Effect of estrogen on endothelial function and angiogenesis. Vascular Pharmacology 38:2, 89-98
CrossRef214
Raimond G.V Smolders, Tatjana E Vogelvang, Velja Mijatovic, W Marchien van Baal, Simone J.M Neele, J.Coen Netelenbos, Peter Kenemans, Marius J van der Mooren. (2002) A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 41:2, 105-114
CrossRef215
H Tapiero, G Nguyen Ba, K.D Tew. (2002) Estrogens and environmental estrogens. Biomedicine & Pharmacotherapy 56:1, 36-44
CrossRef216
Naoyoshi MINAMI, Nobuyoshi MORI, Makoto NAGASAKA, Hajime KUROSAWA, Masayuki KANAZAWA, Masahiro KOHZUKI. (2002) Effect of Estrogen on Pressor Responses to .ALPHA.1-Adrenoreceptor Agonist in Conscious Female Rats.. Hypertension Research 25:4, 609-613
CrossRef217
Becky Kendall, Roger Eston. (2002) Exercise-Induced Muscle Damage and the Potential Protective Role of Estrogen. Sports Medicine 32:2, 103-123
CrossRef218
Ichiro Sakuma, Ming-Yue Liu, Atsushi Sato, Toshio Hayashi, Akihisa Iguchi, Akira Kitabatake, Yuichi Hattori. (2002) Endothelium-dependent hyperpolarization and relaxation in mesenteric arteries of middle-aged rats: influence of oestrogen. British Journal of Pharmacology 135:1, 48-54
CrossRef219
Hiroshi Murakami, Nobuhiro Harada, Hironobu Sasano. (2001) Aromatase in atherosclerotic lesions of human aorta. The Journal of Steroid Biochemistry and Molecular Biology 79:1-5, 67-74
CrossRef220
Kumiko Hirata, Kenei Shimada, Hiroyuki Watanabe, Takashi Muro, Minoru Yoshiyama, Kazuhide Takeuchi, Takeshi Hozumi, Junichi Yoshikawa. (2001) Modulation of coronary flow velocity reserve by gender, menstrual cycle and hormone replacement therapy. Journal of the American College of Cardiology 38:7, 1879-1884
CrossRef221
Marco Gambacciani, Andrea R. Genazzani. (2001) Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 40:3, 195-201
CrossRef222
David Leonardi, Alan P. Mintz, Anton Dotson, Jhoanna Mukai. (2001) Hormone Modulation, Low Glycemic Nutrition, and Exercise Instruction: Effects on Disease Risk and Quality of Life. Journal of Anti-Aging Medicine 4:4, 357-371
CrossRef223
Kwang Kon Koh, Moon Ho Kang, Dong Kyu Jin, Seon-Kyu Lee, Jeong Yeal Ahn, Hee Young Hwang, Seong Hee Yang, Dae Sung Kim, Tae Hoon Ahn, Eak Kyun Shin. (2001) Vascular effects of estrogen in type II diabetic postmenopausal women. Journal of the American College of Cardiology 38:5, 1409-1415
CrossRef224
Nicola Colacurci, Felice Fornaro, Pasquale De Franciscis, Mario Palermo, Walter del Vecchio. (2001) Effects of different types of hormone replacement therapy on mammographic density. Maturitas 40:2, 159-164
CrossRef225
Viscoli, Catherine M., Brass, Lawrence M., Kernan, Walter N., Sarrel, Philip M., Suissa, Samy, Horwitz, Ralph I., . (2001) A Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke. New England Journal of Medicine 345:17, 1243-1249
Full Text226
Adnan I. Qureshi, M. Fareed K. Suri, Abutaher M. Yahia, Jose I. Suarez, Lee R. Guterman, L. Nelson Hopkins, Rafael J. Tamargo. (2001) Risk Factors for Subarachnoid Hemorrhage. Neurosurgery 49:3, 607-613
CrossRef227
Harri J Ranki, Grant R Budas, Russell M Crawford, Aleksandar Jovanović. (2001) Gender-specific difference in cardiac ATP-sensitive K+ channels. Journal of the American College of Cardiology 38:3, 906-915
CrossRef228
Nicola Colacurci, Felice Fornaro, Pasquale De Franciscis, Daniela Mele, Mario Palermo, Walter del Vecchio. (2001) Effects of a short-term suspension of hormone replacement therapy on mammographic density. Fertility and Sterility 76:3, 451-455
CrossRef229
J.E Blümel, C Castelo-Branco, A Sanjuán, P González, C Moyano, T.M Iturriaga, R Gonzalez, S Romero, A Cano. (2001) A simplified method to quantitate atherosclerosis in the rabbit aorta. Maturitas 39:3, 265-271
CrossRef230
P.-G Sator, J.B Schmidt, M.O Sator, J.C Huber, H Hönigsmann. (2001) The influence of hormone replacement therapy on skin ageing. Maturitas 39:1, 43-55
CrossRef231
Charles A. Cefalu, Cathi Fontenot. (2001) The female menopause— now and in the millennium: New treatment options for a better quality of life. Comprehensive Therapy 27:2, 95-103
CrossRef232
Andrea R Genazzani, Marco Gambacciani. (2001) HRT in the third millennium. Maturitas 38, S49-S55
CrossRef233
Yvonne T van der Schouw, Diederick E Grobbee. (2001) HRT and heart disease: Dr Jekyll or Mrs Hyde?. Maturitas 38:3, 213-217
CrossRef234
Annlia Paganini-Hill. (2001) Hormone replacement therapy and stroke: risk, protection or no effect?. Maturitas 38:3, 243-261
CrossRef235
Mitsuhiro Sanada, Yukihito Higashi, Keigo Nakagawa, Shota Sasaki, Ichiro Kodama, Mikio Tsuda, Nobutaka Nagai, Koso Ohama. (2001) Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women. Journal of the American College of Cardiology 37:6, 1529-1535
CrossRef236
S. Leong, J. R. Docherty. (2001) Vascular inhibitory actions of 17beta-oestradiol in rat portal vein. Journal of Autonomic Pharmacology 21:2, 95-99
CrossRef237
Pardeep S Jhund, Nuala Dawson, Andrew P Davie, Naveed Sattar, John Norrie, Kevin P.J O’Kane, John J.V McMurray. (2001) Attenuation of endothelin-1 induced vasoconstriction by 17β estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. Journal of the American College of Cardiology 37:5, 1367-1373
CrossRef238
Antonino Saitta, Nunziate Morabito, Nicola Frisina, Domenico Cucinotte, Francesco Corrado, Rosario D'Anna, Domenica Altavilla, Giovanni Squadrito, Letteria Minutoli, Vincenzo Arcoraci, Francesco Cancellieri, Francesco Squadrito. (2001) Cardiovascular Effects of Raloxifene Hydrochloride. Cardiovascular Drug Reviews 19:1, 57-74
CrossRef239
Madelon L. Finkel, Maurice Cohen, Heather Mahoney. (2001) Treatment Options for the Menopausal Woman. The Nurse Practitioner5-7, 11-15
CrossRef240
B. Muller, D. A. Tsakiris, C. B. Roth, M. Guglielmetti, J.-J. Staub, G. A. Marbet. (2001) Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. European Journal of Clinical Investigation 31:2, 131-137
CrossRef241
S. E. Reis, J. P. Costantino, D. L. Wickerham, E. Tan-Chiu, J. Wang, M. Kavanah. (2001) Cardiovascular Effects of Tamoxifen in Women With and Without Heart Disease: Breast Cancer Prevention Trial. JNCI Journal of the National Cancer Institute 93:1, 16-21
CrossRef242
Lynda B. Ransdell. (2001) A Chronology of the Study of Older Women's Health: Data, Discoveries, and Future Directions. Journal of Women & Aging 13:1, 39-55
CrossRef243
Jean-Charles Fruchart, Bart Staels, Patrick Duriez. (2001) The role of fibric acids in atherosclerosis. Current Atherosclerosis Reports 3:1, 83-92
CrossRef244
Kazushi TSUDA, Yukiko SHIMAMOTO, Keizo KIMURA, Ichiro NISHIO, Yoshiaki MASUYAMA. (2001) Estriol Improves Membrane Fluidity of Erythrocytes by the Nitric Oxide-Dependent Mechanism: An Electron Paramagnetic Resonance Study.. Hypertension Research 24:3, 263-269
CrossRef245
Sirpa Eviö, Aila Tiitinen, Ursula Turpeinen, Olavi Ylikorkala. (2000) Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertility and Sterility 74:6, 1080-1083
CrossRef246
Philip J. DiSaia, Wendy R. Brewster, Argyrios Ziogas, Hoda Anton-Culver. (2000) Breast Cancer Survival and Hormone Replacement Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials 23:6, 541-545
CrossRef247
T S Tsang, M E Barnes, B J Gersh, S N Hayes. (2000) Risks of coronary heart disease in women: current understanding and evolving concepts.. Mayo Clinic Proceedings 75:12, 1289-1303
CrossRef248
Florence A. Tremollieres, Fabienne Cigagna, Cathy Alquier, Colette Cauneille, Jean-Michel Pouilles, Claude Ribot. (2000) Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women. Atherosclerosis 153:1, 81-88
CrossRef249
Tokumitsu Watanabe, Masahiro Akishita, Kenji Toba, Koichi Kozaki, Masato Eto, Naota Sugimoto, Takahiro Kiuchi, Masayoshi Hashimoto, Wataru Shirakawa, Yasuyoshi Ouchi. (2000) Influence of sex and age on serum nitrite/nitrate concentration in healthy subjects. Clinica Chimica Acta 301:1-2, 169-179
CrossRef250
Diane Zanger, Benjamin K Yang, Jeanette Ardans, Myron A Waclawiw, Gyorgy Csako, Larry M Wahl, Richard O Cannon. (2000) Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. Journal of the American College of Cardiology 36:6, 1797-1802
CrossRef251
Claes Ohlsson, Nina Hellberg, Paolo Parini, Olle Vidal, Mohammed Bohlooly, Mats Rudling, Marie K. Lindberg, Margaret Warner, Bo Angelin, Jan-Åke Gustafsson. (2000) Obesity and Disturbed Lipoprotein Profile in Estrogen Receptor-α-Deficient Male Mice. Biochemical and Biophysical Research Communications 278:3, 640-645
CrossRef252
John E Piletz, Uriel Halbreich. (2000) Imidazoline and α2a-adrenoceptor binding sites in postmenopausal women before and after estrogen replacement therapy. Biological Psychiatry 48:9, 932-939
CrossRef253
Hanneke W. Wilmink, Miriam J.J. de Kleijn, Michiel L. Bots, Annette A.A. Bak, Yvonne T. van der Schouw, Sylvia Engelen, Jose Planellas, Jan-Dirk Banga, Diederick E. Grobbee. (2000) Lipoprotein (a) is associated with endothelial function in healthy postmenopausal women. Atherosclerosis 153:1, 249-254
CrossRef254
John C Stevenson. (2000) Cardiovascular effects of oestrogens. The Journal of Steroid Biochemistry and Molecular Biology 74:5, 387-393
CrossRef255
Hubert H. Fernandez, Kate L. Lapane. (2000) Estrogen use among nursing home residents with a diagnosis of Parkinson's disease. Movement Disorders 15:6, 1119-1124
CrossRef256
Michael E Mendelsohn. (2000) Mechanisms of estrogen action in the cardiovascular system. The Journal of Steroid Biochemistry and Molecular Biology 74:5, 337-343
CrossRef257
Bernardo Bonanni, Aliana Guerrieri-Gonzaga, Nicole Rotmensz, Rosalba Torrisi, Francesca Pigatto, Massimiliano Cazzaniga, Serena Mora, Silvia Diani, Chris Robertson, Andrea Decensi. (2000) Hormonal Therapy and Chemoprevention. The Breast Journal 6:5, 317-323
CrossRef258
Céline Martel, Sylvain Picard, Virgile Richard, Alain Bélanger, Claude Labrie, Fernand Labrie. (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. The Journal of Steroid Biochemistry and Molecular Biology 74:1-2, 45-56
CrossRef259
Maureen T. Connelly, Marcie Richardson, Richard Platt. (2000) Prevalence and Duration of Postmenopausal Hormone Replacement Therapy Use in a Managed Care Organization, 1990-1995. Journal of General Internal Medicine 15:8, 542-550
CrossRef260
Delyth Clemett, Caroline M. Spencer. (2000) Raloxifene. Drugs 60:2, 379-411
CrossRef261
Concepción Ceballos, Constantino Ribes, José A Amado, Josefina Pérez, Marı́a Teresa Garcı́a Unzueta, José R de Berrazueta. (2000) Venous endothelial function in postmenopausal women who are receiving long-term estrogen and progestagen therapy. Fertility and Sterility 74:2, 268-273
CrossRef262
Doraid Jarrar, Ping Wang, Markus W. Knöferl, Joachim F. Kuebler, William G. Cioffi, Kirby I. Bland, Irshad H. Chaudry. (2000) Insight into the mechanism by which estradiol improves organ functions after trauma-hemorrhage. Surgery 128:2, 246-252
CrossRef263
Colin T. McDonald, Walter J. Koroshetz. (2000) Transient ischemic attack and secondary stroke. Current Treatment Options in Neurology 2:4, 329-341
CrossRef264
Chandrasekharan Ramachandran, David Fleisher. (2000) Transdermal delivery of drugs for the treatment of bone diseases. Advanced Drug Delivery Reviews 42:3, 197-223
CrossRef265
Shizuka Sasazuki, Hiroko Kodama, Kouichi Yoshimasu, Ying Liu, Masakazu Washio, Keitaro Tanaka, Shoji Tokunaga, Suminori Kono, Hidekazu Arai, Yoshitaka Doi, Tomoki Kawano, Osamu Nakagaki, Kazuyuki Takada, Samon Koyanagi, Koji Hiyamuta, Takanobu Nii, Kazuyuki Shirai, Munehito Ideishi, Kikuo Arakawa, Masahiro Mohri, Akira Takeshita. (2000) Relation between Green Tea Consumption and the Severity of Coronary Atherosclerosis among Japanese Men and Women. Annals of Epidemiology 10:6, 401-408
CrossRef266
Pattie S. Green, James W. Simpkins. (2000) Neuroprotective effects of estrogens: potential mechanisms of action. International Journal of Developmental Neuroscience 18:4-5, 347-358
CrossRef267
Judith M Steel. (2000) Why, as a woman interested in women's health and diabetes, I am not rushing to put my patients on HRT. Practical Diabetes International 17:5, 163-164
CrossRef268
Konen Obayashi, Yukio Ando, Masaaki Nakamura, Hisayasu Terazaki, Taro Yamashita, Kazuhiro Tashima, Moritaka Suga, Makoto Uchino, Masayuki Ando. (2000) Endothelium-dependent vasodilatation in patients with familial amyloidotic polyneuropathy. Muscle & Nerve 23:7, 1084-1088
CrossRef269
Takayuki Sasaki, Yoichi Ohno, Keiichi Otsuka, Taichi Suzawa, Hiromichi Suzuki, Takao Saruta. (2000) Oestrogen attenuates the increases in blood pressure and platelet aggregation in ovariectomized and salt-loaded Dahl salt-sensitive rats. Journal of Hypertension 18:7, 911-917
CrossRef270
Harald Seeger, Alfred O. Mueck, Theodor H. Lippert. (2000) Effects of valsartan and 17β-estradiol on the oxidation of low-density lipoprotein in vitro. Coronary Artery Disease 11:4, 347-349
CrossRef271
Gemma A Figtree, Huw Griffiths, Ying-Qing Lu, Carolyn M Webb, Kenneth MacLeod, Peter Collins. (2000) Plant-derived estrogens relax coronary arteries in vitro by a calcium antagonistic mechanism. Journal of the American College of Cardiology 35:7, 1977-1985
CrossRef272
Anne Johanne Søgaard, Anne Tollan, Gro K.R Berntsen, Vinjar Fønnebø, Jeanette H Magnus. (2000) Hormone replacement therapy:. Maturitas 35:3, 201-214
CrossRef273
Diana Kuh, Rebecca Hardy, Michael Wadsworth. (2000) Social and behavioural influences on the uptake of hormone replacement therapy among younger women. BJOG: An International Journal of Obstetrics and Gynaecology 107:6, 731-739
CrossRef274
E.Bernd Ringelstein, Darius Nabavi. (2000) Long-Term Prevention of Ischaemic Stroke and Stroke Recurrence. Thrombosis Research 98:3, 83-96
CrossRef275
Fran Kaiser. 2000. Sexuality in the Menopausal Years and Beyond. , 317-327.
CrossRef276
Hwee Teoh, Adrian Quan, Susan W S Leung, Ricky Y K Man. (2000) Differential effects of 17 β -estradiol and testosterone on the contractile responses of porcine coronary arteries. British Journal of Pharmacology 129:7, 1301-1308
CrossRef277
Hwee Teoh, Ricky Y K Man. (2000) Enhanced relaxation of porcine coronary arteries after acute exposure to a physiological level of 17β-estradiol involves non-genomic mechanisms and the cyclic AMP cascade. British Journal of Pharmacology 129:8, 1739-1747
CrossRef278
T. Hayashi, I. Ito, H. Kano, H. Endo, A. Iguchi. (2000) Estriol (E3) Replacement Improves Endothelial Function and Bone Mineral Density in Very Elderly Women. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 55:4, B183-B190
CrossRef279
Paul Manwaring, Litsa Morfis, Terence Diamond, Laurence G Howes. (2000) The effects of hormone replacement therapy on plasma lipids in type II diabetes. Maturitas 34:3, 239-247
CrossRef280
Inger Byrjalsen, Peter Alexandersen, Glaus Christiansen. (2000) Piperazine oestrone sulphate and interrupted norethisterone: effects on the postmenopausal endometrium. BJOG: An International Journal of Obstetrics and Gynaecology 107:3, 347-355
CrossRef281
Melissa Calvin. (2000) Oestrogens and wound healing. Maturitas 34:3, 195-210
CrossRef282
Lisa M. Harrison-Bernard, Leopoldo Raij. (2000) Postmenopausal hypertension. Current Hypertension Reports 2:2, 202-207
CrossRef283
Marita Paassilta, Anna Karjalainen, Kari Kervinen, Markku J Savolainen, Jorma Heikkinen, Ann-Christine Bäckström, Y.Antero Kesäniemi. (2000) Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis 149:1, 157-162
CrossRef284
Dorothy R. Pathak, Janet R. Osuch, Jianping He. (2000) Breast carcinoma etiology. Cancer 88:S5, 1230-1238
CrossRef285
Mitchell S. Cappell, Jeffrey R. Schein. (2000) DIAGNOSIS AND TREATMENT OF NONSTEROIDAL ANTI-INFLAMMATORY DRUG-ASSOCIATED UPPER GASTROINTESTINAL TOXICITY. Gastroenterology Clinics of North America 29:1, 97-124
CrossRef286
Arnon Blum, Kwang Koh, Richard O. Cannon. (2000) Hormone Replacement Therapy for Prevention or Treatment of Atherosclerosis in Postmenopausal Women: Promises, Controversies, and Clinical Trials. The American Journal of Geriatric Cardiology 9:2, 81-90
CrossRef287
Theo Pelzer, Michael Schumann, Manfred Neumann, Tertia deJager, Michael Stimpel, E. Serfling, Ludwig Neyses. (2000) 17β-Estradiol Prevents Programmed Cell Death in Cardiac Myocytes. Biochemical and Biophysical Research Communications 268:1, 192-200
CrossRef288
Cora E. Lewis, Janet Y. Groff, Carla J. Herman, Robert E. McKeown, Lynne S. Wilcox. (2000) Overview of Women's Decision Making Regarding Elective Hysterectomy, Oophorectomy, and Hormone Replacement Therapy. Journal of Women's Health & Gender-Based Medicine 9:supplement 2, 5-14
CrossRef289
Thomas von Holst, Birgitt Salbach. (2000) Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints. Maturitas 34:2, 143-153
CrossRef290
Ruth Freeman. (2000) Hormone Replacement Therapy (Estrogen and Progesterone): Is it Necessary for Heart Disease Prevention?. Preventive Cardiology 3:1, 21-24
CrossRef291
Keith Griffiths, Louis J. Denis. (2000) Exploitable mechanisms for the blockade of androgenic action. The Prostate 45:S10, 43-51
CrossRef292
Noriko Kikuchi, Mamoru Urabe, Koichi Iwasa, Tomoharu Okubo, Hiroshi Tsuchiya, Tetsuya Hosoda, Hiroshi Tatsumi, Hideo Honjo. (2000) Atheroprotective effect of estriol and estrone sulfate on human vascular smooth muscle cells. The Journal of Steroid Biochemistry and Molecular Biology 72:1-2, 71-78
CrossRef293
Michael G Jakoby, Clay F Semenkovich. (2000) The role of osteoprogenitors in vascular calcification. Current Opinion in Nephrology and Hypertension 9:1, 11-15
CrossRef294
Bryan L. Haddock, Helen P. Hopp Marshak, Jenifer J. Mason, Glen Blix. (2000) The Effect of Hormone Replacement Therapy and Exercise on Cardiovascular Disease Risk Factors in Postmenopausal Women. Sports Medicine 29:1, 39-49
CrossRef295
Ali Serdar Fak, Mithat Erenus, Hakan Tezcan, Oguz Caymaz, Sule Oktay, Ahmet Oktay. (2000) Effects of a single dose of oral estrogen on left ventricular diastolic function in hypertensive postmenopausal women with diastolic dysfunction. Fertility and Sterility 73:1, 66-71
CrossRef296
NICOLE A. SEMINARIO, ROBERT R. SCIACCA, MARCO R. DiTULLIO, SHUNICHI HOMMA, ELSA-GRACE V. GIARDINA. (1999) Effect of Age on the Exercise Response in Normal Postmenopausal Women during Estrogen Replacement Therapy. Journal of Women's Health & Gender-Based Medicine 8:10, 1273-1279
CrossRef297
Joseph P. Frolkis. (1999) SCREENING FOR CARDIOVASCULAR DISEASE. Medical Clinics of North America 83:6, 1339-1373
CrossRef298
Ozgul Muneyyirci-Delale, Mudar Dalloul, Vijaga L Nacharaju, Burton M Altura, Bella T Altura. (1999) Serum ionized magnesium and calcium and sex hormones in healthy young men: importance of serum progesterone level. Fertility and Sterility 72:5, 817-822
CrossRef299
Cristina Bosetti, Eva Negri, Alessandra Tavani, Luigi Santoro, Carlo La Vecchia. (1999) Smoking and Acute Myocardial Infarction among Women and Men: A Case–Control Study in Italy. Preventive Medicine 29:5, 343-348
CrossRef300
Hartmut Hanke, Joachim Kamenz, Sybille Hanke, Jochen Spieß, Christina Lenz, U. Brehme, Birgit Bruck, Gerald Finking, Vinzenz Hombach. (1999) Effect of 17-β estradiol on pre-existing atherosclerotic lesions: role of the endothelium. Atherosclerosis 147:1, 123-132
CrossRef301
Ellis R. Levin. (1999) Cellular Functions of the Plasma Membrane Estrogen Receptor. Trends in Endocrinology & Metabolism 10:9, 374-377
CrossRef302
Stephanie Hügel, Martin Reincke, Hinrik Strömer, Johannes Winning, Michael Horn, Charlotte Dienesch, Patricia Mora, Harald H.H.W. Schmidt, Bruno Allolio, Stefan Neubauer. (1999) Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling. Journal of the American College of Cardiology 34:5, 1427-1434
CrossRef303
L.V. Avioli. (1999) SERM Drugs for the Prevention of Osteoporosis. Trends in Endocrinology & Metabolism 10:8, 317-319
CrossRef304
Francesca Chiaffarino, Fabio Parazzini, Carlo La Vecchia, Massimiliano Maria Bianchi, Guido Benzi, Elena Ricci, Vito Chiantera. (1999) Correlates of hormone replacement therapy use in Italian women, 1992–1996. Maturitas 33:2, 107-115
CrossRef305
Ulla Pripp, Gerd Hall, György Csemiczky, Staffan Eksborg, Britt-Marie Landgren, Karin Schenck-Gustafsson. (1999) A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. Journal of Hypertension 17:10, 1379-1386
CrossRef306
Chris Spencer, David Crook, David Ross, Alison Cooper, Malcolm Whitehead, John Stevenson. (1999) A randomised comparison of the effects of oral versus transdermal 17beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels. BJOG: An International Journal of Obstetrics and Gynaecology 106:9, 948-953
CrossRef307
Thomas A Wilson, Robert J Nicolosi, Carl W Lawton, John Babiak. (1999) Gender differences in response to a hypercholesterolemic diet in hamsters: effects on plasma lipoprotein cholesterol concentrations and early aortic atherosclerosis. Atherosclerosis 146:1, 83-91
CrossRef308
Janice K Crews, Raouf A Khalil. (1999) Gender-Specific Inhibition of Ca2+ Entry Mechanisms of Arterial Vasoconstriction by Sex Hormones. Clinical and Experimental Pharmacology and Physiology 26:9, 707-715
CrossRef309
L Chmouliovsky, F Habicht, R.W James, T Lehmann, A Campana, A Golay. (1999) Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. Maturitas 32:3, 147-153
CrossRef310
Ketil Bjarnason, Åsta Cerin, Richard Lindgren, Tom Weber. (1999) Adverse endometrial effects during long cycle hormone replacement therapy. Maturitas 32:3, 161-170
CrossRef311
Gillian Ladd Lautenbach, Michelle Petri. (1999) WOMEN'S HEALTH. Rheumatic Disease Clinics of North America 25:3, 539-565
CrossRef312
Harald Seeger, Alfred O. Mueck, Theodor H. Lippert. (1999) Effect of estradiol metabolites on prostacyclin synthesis in human endothelial cell cultures. Life Sciences 65:13, PL167-PL170
CrossRef313
D Hochner-Celnikier. (1999) Pharmacokinetics of raloxifene and its clinical application. European Journal of Obstetrics & Gynecology and Reproductive Biology 85:1, 23-29
CrossRef314
P. Polterauer, J. Nanobachvili, A. Fügl. (1999) Chirurgische Gefäßmedizin der Zukunft: interdisziplinäre Strategien. European Surgery 31:4, 235-242
CrossRef315
Wulf H. Utian, Kenneth A. Burry, David F. Archer, John C. Gallagher, Robert L. Boyett, Martine P. Guy, Gilles J. Tachon, Harbajan K. Chadha-Boreham, Agnès A. Bouvet. (1999) Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. American Journal of Obstetrics and Gynecology 181:1, 71-79
CrossRef316
Linda A. Lacharity. (1999) The Experiences of Younger Women with Coronary Artery Disease. Journal of Women's Health & Gender-Based Medicine 8:6, 773-785
CrossRef317
Patrick Duriez, Jean-Charles Fruchart. (1999) Recent developments in the treatment of hypertriglyceridemia. Current Atherosclerosis Reports 1:1, 31-37
CrossRef318
Jean E. Mulder. (1999) Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure. Medical and Pediatric Oncology 33:1, 46-52
CrossRef319
Jill B. Jones. (1999) Hormone Replacement Therapy. Social Work in Health Care 28:3, 95-111
CrossRef320
Epstein, Franklin H., , Mendelsohn, Michael E., Karas, Richard H., . (1999) The Protective Effects of Estrogen on the Cardiovascular System. New England Journal of Medicine 340:23, 1801-1811
Full Text321
Asko Järvinen, Sirkka Nykänen, Leena Paasiniemi. (1999) Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 32:2, 103-113
CrossRef322
Jenny Tse, Baby Martin-McNaulty, Meredith Halks-Miller, Katalin Kauser, Virginia DelVecchio, Ronald Vergona, Mark E Sullivan, Gabor M Rubanyi. (1999) Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17β-estradiol. Atherosclerosis 144:2, 303-313
CrossRef323
SUSAN S. GIRDLER, COLLEEN O'BRIANT, JOHN STEEGE, KAREN GREWEN, KATHLEEN C. LIGHT. (1999) A Comparison of the Effect of Estrogen with or without Progesterone on Mood and Physical Symptoms in Postmenopausal Women. Journal of Women's Health & Gender-Based Medicine 8:5, 637-646
CrossRef324
Curt W Burger, Flora E van Leeuwen, Fedde Scheele, Peter Kenemans. (1999) Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 32:2, 69-76
CrossRef325
Raymond J. Gibbons, Kanu Chatterjee, Jennifer Daley, John S. Douglas, Stephan D. Fihn, Julius M. Gardin, Mark A. Grunwald, Daniel Levy, Bruce W. Lytle, Robert A. O’Rourke, William P. Schafer, Sankey V. Williams, James L. Ritchie, Raymond J. Gibbons, Melvin D. Cheitlin, Kim A. Eagle, Timothy J. Gardner, Arthur Garson, Richard O. Russell, Thomas J. Ryan, Sidney C. Smith. (1999) ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. Journal of the American College of Cardiology 33:7, 2092-2197
CrossRef326
Katalin Kauser, Gabor M. Rubanyi. (1999) Estrogen and nitric oxide in vasculature. Current Opinion in Endocrinology & Diabetes 6:3, 230
CrossRef327
P. Harvey. (1999) Oestrogen and vascular disease. Australian and New Zealand Journal of Medicine 29:3, 473-479
CrossRef328
Jürgen R. Reichenbach, Christian Przetak, Gottwalt Klinger, Werner A. Kaiser. (1999) Assessment of Breast Tissue Changes on Hormonal Replacement Therapy Using MRI: A Pilot Study. Journal of Computer Assisted Tomography 23:3, 407-413
CrossRef329
B. Griewing, Th. Römer, C. Spitzer, J. Lüdemann, A. Günther, Ch. Kessler. (1999) Hormone replacement therapy in postmenopausal women: carotid intima-media thickness and 3-D volumetric plaque quantification. Maturitas 32:1, 33-40
CrossRef330
Vuong N. Trieu, Fatih M. Uckun. (1999) Genistein Is Neuroprotective in Murine Models of Familial Amyotrophic Lateral Sclerosis and Stroke. Biochemical and Biophysical Research Communications 258:3, 685-688
CrossRef331
A.R. Genazzani, M. Gambacciani. (1999) Hormone replacement therapy: the perspectives for the 21st century. Maturitas 32:1, 11-17
CrossRef332
Rolf Alwers, Jaime Urdinola, William Onatra, Fabio Sánchez, Hector Posso. (1999) Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Maturitas 32:1, 41-50
CrossRef333
P.M. Stewart, M.C. Sheppard. (1999) Mortality and hypopituitarism. Growth Hormone & IGF Research 9, 15-19
CrossRef334
S.R Davis. (1999) The therapeutic use of androgens in women. The Journal of Steroid Biochemistry and Molecular Biology 69:1-6, 177-184
CrossRef335
Tamara K. Waddell, Chakravarthi Rajkumar, James D. Cameron, Garry L. Jennings, Anthony M. Dart, Bronwyn A. Kingwell. (1999) Withdrawal of hormonal therapy for 4 weeks decreases arterial compliance in postmenopausal women. Journal of Hypertension 17:3, 413-418
CrossRef336
Peter W. F. Wilson. (1999) Metabolic risk factors for coronary heart disease: current and future prospects. Current Opinion in Cardiology 14:2, 176
CrossRef337
Jeffrey A. Kotzan, Bradley C. Martin, William E. Wade. (1999) Persistence with Estrogen Therapy in a Postmenopausal Medicaid Population. Pharmacotherapy 19:3, 363-369
CrossRef338
Malcolm M. Bilimoria, David J. Winchester, Stephen F. Sener, Gary Motykie, Uday L. Sehgal, David P. Winchester. (1999) Estrogen Replacement Therapy and Breast Cancer: Analysis of Age of Onset and Tumor Characteristics. Annals of Surgical Oncology 6:2, 200-207
CrossRef339
F J Nieto. (1999) Cardiovascular disease and risk factor epidemiology: a look back at the epidemic of the 20th century.. American Journal of Public Health 89:3, 292-294
CrossRef340
D. Singer, M. Hunter. (1999) The experience of premature menopause: A thematic discourse analysis. Journal of Reproductive and Infant Psychology 17:1, 63-81
CrossRef341
Aedin Cassidy, Bruce Griffin. (1999) Phyto-oestrogens: A potential role in the prevention of CHD?. Proceedings of the Nutrition Society 58:01, 193-199
CrossRef342
Florence A. Trémollières, Jean-Michel Pouilles, Colette Cauneille, Claude Ribot. (1999) Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis 142:2, 415-423
CrossRef343
George M. Twaddle, Jane Turbov, Naxin Liu, Satya Murthy. (1999) Tyrosine kinase inhibitors as antiproliferative agents against an estrogen-dependent breast cancer cell line in vitro. Journal of Surgical Oncology 70:2, 83-90
CrossRef344
Irina Virtanen, Paivi Polo-Kantola, Risto Erkkola, Olli Polo, Eeva Ekholm. (1999) Climacteric vasomotor symptoms do not imply autonomic dysfunction. BJOG: An International Journal of Obstetrics and Gynaecology 106:2, 155-164
CrossRef345
Ettore Cicinelli, Louis J. Ignarro, Maria Giuseppina Matteo, Pietro Galantino, Luca Maria Schonauer, Nunziata Falco. (1999) Effects of estrogen replacement therapy on plasma levels of nitric oxide in postmenopausal women. American Journal of Obstetrics and Gynecology 180:2, 334-339
CrossRef346
Siv Fossum, Nils-Ove Hoem, Halvard Gjønnæss, Kjell Briseid. (1999) Contact Activation Factors in Plasma from Women on Estrogen Replacement Therapy after Ovariohysterectomy. Thrombosis Research 93:4, 161-170
CrossRef347
V. NIKOLAIDOU-POLITIS. (1999) Effects of hormone replacement therapy on serum lipids and phospholipids in postmenopausal women. Journal of Obstetrics & Gynaecology 19:2, 184-189
CrossRef348
G. Finking, Beate Hess, H. Hanke. (1999) The value of phytoestrogens as a possible therapeutic option in postmenopausal women with coronary heart disease. Journal of Obstetrics & Gynaecology 19:5, 455-459
CrossRef349
Donald M Lloyd-Jones, Martin G Larson, Alexa Beiser, Daniel Levy. (1999) Lifetime risk of developing coronary heart disease. The Lancet 353:9147, 89-92
CrossRef350
Heidi L Andersen, Jan U Weis, Bjarne Fjalland, Niels Korsgaard. (1999) Effect of acute and long-term treatment with 17- β -estradiol on the vasomotor responses in the rat aorta. British Journal of Pharmacology 126:1, 159-168
CrossRef351
Maria Petersson, Thomas Lundeberg, Kerstin Uvnäs-Moberg. (1999) Short-Term Increase and Long-Term Decrease of Blood Pressure in Response to Oxytocin-Potentiating Effect of Female Steroid Hormones. Journal of Cardiovascular Pharmacology 33:1, 102-108
CrossRef352
Steven R. Goldstein. (1998) Selective estrogen receptor modulators: A new category of therapeutic agents for extending the health of postmenopausal women. American Journal of Obstetrics and Gynecology 179:6, 1479-1484
CrossRef353
L Sourander, T Rajala, I Räihä, J Mäkinen, R Erkkola, H Helenius. (1998) Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). The Lancet 352:9145, 1965-1969
CrossRef354
Arnon Blum, Richard O. Cannon. (1998) Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function. Current Opinion in Lipidology 9:6, 575-586
CrossRef355
Allon Nechmad, Gideon Merin, Herzl Schwalb, Dov V. Shimon, Joseph B. Borman, Eli Milgalter, Morris Mosseri. (1998) Estrogen Induces Nitric Oxide-Mediated Vasodilation of Human Mammary Arteriesin Vitro. Nitric Oxide 2:6, 460-466
CrossRef356
Matthias Barton, Jochen Cremer, Andreas Mügge. (1998) 17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. European Journal of Pharmacology 362:1, 73-76
CrossRef357
Vanina Bongard, Jean Ferrières, Jean-Bernard Ruidavets, Philippe Amouyel, Dominique Arveiler, Annie Bingham, Pierre Ducimetière. (1998) Transdermal estrogen replacement therapy and plasma lipids in 693 French women. Maturitas 30:3, 265-272
CrossRef358
Isha A. Mustafa, Kirby I. Bland. (1998) Physiologic Effects of Steroid Hormones and Postmenopausal Hormone Replacement on the Female Breast and Breast Cancer Risk. Annals of Surgery 228:5, 638-651
CrossRef359
Lydia Ioannidou-Mouzaka, George N. Peters. (1998) Dilemmas in Breast Disease. The Breast Journal 4:6, 465-469
CrossRef360
Leon Speroff. (1998) The Heart and Estrogen/progestin Replacement Study (HERS). Maturitas 31:1, 9-14
CrossRef361
EVELYN P. WHITLOCK, RICHARD E. JOHNSON, THOMAS M. VOGT. (1998) Recent Patterns of Hormone Replacement Therapy Use in a Large Managed Care Organization. Journal of Women's Health 7:8, 1017-1026
CrossRef362
Lorella G. Thomas, Elizabeth J. Corwin. (1998) The Readability of Printed Education Materials Regarding Hormone Replacement Therapy. Journal of the American Academy of Nurse Practitioners 10:10, 447-452
CrossRef363
EARL S. FORD, JULIE C. WILL, MARTINE A. DE PROOST FORD, ALI H. MOKDAD. (1998) Health Insurance Status and Cardiovascular Disease Risk Factors among 50–64-Year-Old U.S. Women: Findings from the Third National Health and Nutrition Examination Survey. Journal of Women's Health 7:8, 997-1006
CrossRef364
Masahiro Akishita, Koichi Kozaki, Masato Eto, Masao Yoshizumi, Michiro Ishikawa, Kenji Toba, Hajime Orimo, Yasuyoshi Ouchi. (1998) Estrogen Attenuates Endothelin-1 Production by Bovine Endothelial Cells via Estrogen Receptor. Biochemical and Biophysical Research Communications 251:1, 17-21
CrossRef365
Elizabeth S. Ginsburg, Brian Walsh, Louise Greenberg, Deborah Price, Glenn M. Chertow, William F. Owen. (1998) Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. Kidney International 54:4, 1344-1350
CrossRef366
Bernard Blanc, Ludovic Cravello, Marie-Christine Micheletti, Claude d'Ercole, Marie Zartarian. (1998) Continuous hormone replacement therapy for menopause combining nomegestrol acetate and gel, patch, or oral estrogen: a comparison of amenorrhea rates. Clinical Therapeutics 20:5, 901-912
CrossRef367
Jonggonnee Wattanapermpool. (1998) Increase in calcium responsiveness of cardiac myofilament activation in ovariectomized rats. Life Sciences 63:11, 955-964
CrossRef368
Tze K. Lau, Din Wan, So F. Yim, John E. Sanderson, Christopher J. Haines. (1998) Prospective, randomized, controlled study of the effect of hormone replacement therapy on peripheral blood flow velocity in postmenopausal women. Fertility and Sterility 70:2, 284-288
CrossRef369
Vishnudutt Purohit. (1998) Moderate Alcohol Consumption and Estrogen Levels in Postmenopausal Women: A Review. Alcoholism: Clinical and Experimental Research 22:5, 994-997
CrossRef370
Cosimo Massafra, Claudio De Felice, Dino Gioia, Giuseppe Buonocore. (1998) Variations in erythrocyte antioxidant glutathione peroxidase activity during the menstrual cycle. Clinical Endocrinology 49:1, 63-67
CrossRef371
T Mikkola. (1998) Estrogen and postmenopausal estrogen/progestin therapy: effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production. European Journal of Obstetrics & Gynecology and Reproductive Biology 79:1, 75-82
CrossRef372
F.P.M.J Groeneveld, F.P Bareman, R Barentsen, H.J Dokter, A.C Drogendijk, A.W Hoes. (1998) Duration of hormonal replacement therapy in general practice; a follow-up study. Maturitas 29:2, 125-131
CrossRef373
TALYA N. WALDMAN. (1998) Menopause: When Hormone Replacement Therapy Is Not an Option. Journal of Women's Health 7:5, 559-565
CrossRef374
Kevin C.R. Baynes, Juliet E. Compston. (1998) Selective oestrogen receptor modulators: a new paradigm for HRT. Current Opinion in Obstetrics and Gynaecology 10:3, 189-192
CrossRef375
K.L.M. Liao, M.S. Hunter. (1998) Preparation for menopause: prospective evaluation of a health education intervention for mid-aged women. Maturitas 29:3, 215-224
CrossRef376
Glenn T Shwaery, Joseph A Vita, John F Keaney. (1998) Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17-beta-estradiol. Atherosclerosis 138:2, 255-262
CrossRef377
Subodh Arora, Aristidis Veves, A.Enrique Caballaro, Paula Smakowski, Frank W. LoGerfo. (1998) Estrogen improves endothelial function. Journal of Vascular Surgery 27:6, 1141-1147
CrossRef378
Teresa Caulin-Glaser, William J Farrell, Steven E Pfau, Barry Zaret, Katherine Bunger, John F Setaro, Joseph J Brennan, Jeffrey R Bender, Michael W Cleman, Henry S Cabin, Michael S Remetz. (1998) Modulation of Circulating Cellular Adhesion Molecules in Postmenopausal Women With Coronary Artery Disease. Journal of the American College of Cardiology 31:7, 1555-1560
CrossRef379
David R Halbert, Tom Lloyd, Nan Rollings, Wendy Kowalski, Elizabeth Mauger. (1998) Hormone replacement therapy usage: a 10 year experience of a solo practitioner. Maturitas 29:1, 67-73
CrossRef380
PH Davies, AH Barnett. (1998) Hormone replacement therapy in women with diabetes mellitus: A survey of knowledge of risks and benefits. Practical Diabetes International 15:3, 78-81
CrossRef381
DONNA OTTER, CLARE AUSTIN. (1998) Effects of 17β-Oestradiol on Rat Isolated Coronary and Mesenteric Artery Tone: Involvement of Nitric Oxide. Journal of Pharmacy and Pharmacology 50:5, 531-538
CrossRef382
Simon Jackson, Sanjay Vyas. (1998) A double-blind, placebo controlled study of postmenopausal oestrogen replacement therapy and carotid artery pulsatility index. BJOG: An International Journal of Obstetrics and Gynaecology 105:4, 408-412
CrossRef383
Bantwal Ramanath Rao. (1998) Isolation and characterization of an estrogen binding protein which may integrate the plethora of estrogenic actions in non-reproductive organs. The Journal of Steroid Biochemistry and Molecular Biology 65:1-6, 3-41
CrossRef384
Sam Cathapermal, Mark C. Lavigne, Mann Leong-Son, Thais Alibadi, Peter W. Ramwell. (1998) Stereoisomer-Specific Inhibition of Superoxide Anion-Induced Rat Aortic Smooth-Muscle Cell Proliferation by 17β-Estradiol is Estrogen Receptor Dependent. Journal of Cardiovascular Pharmacology 31:4, 499-505
CrossRef385
Satyendra Giri, Paul D Thompson, Pam Taxel, John H Contois, James Otvos, Robert Allen, Gordon Ens, Alan H.B Wu, David D Waters. (1998) Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 137:2, 359-366
CrossRef386
M. Penotti, L. Sironi, L. Miglierina, M. Farina, L. Barletta, L. Gabrielli, M. Vignali. (1998) The effect of tamoxifen and transdermal 17β-estradiol on cerebral arterial vessels: A randomized controlled study. American Journal of Obstetrics and Gynecology 178:4, 801-805
CrossRef387
Brian D. Golden. (1998) The prevention and treatment of osteoporosis. Arthritis Care & Research 11:2, 124-134
CrossRef388
Jonathan Abrams. (1998) Hormones and the cardiologist. Clinical Cardiology 21:3, 218-222
CrossRef389
N. Ulloa, C. Verdugo, M. Rios, J. Sepúlveda, S. Sepúlveda, R. Naveas, C. Calvo. (1998) Increased activity of lecithin: Cholesterol acyltransferase during short-term oral estrogen progestin replacement therapy in a group of postmenopausal women. Metabolism 47:3, 297-300
CrossRef390
J. Binko, TV Murphy, H. Majewski. (1998) 17?-OESTRADIOL ENHANCES NITRIC OXIDE SYNTHASE ACTIVITY IN ENDOTHELIUM-DENUDED RAT AORTA. Clinical and Experimental Pharmacology and Physiology 25:2, 120-127
CrossRef391
Anil K. Rattan, Yadon Arad. (1998) Inhibition of LDL oxidation by a new estradiol receptor modulator compound LY-139478, comparative effect with other steroids. Atherosclerosis 136:2, 305-314
CrossRef392
Yu-Qi Zhang, Jiong Shi, Gopal Rajakumar, Arthur L Day, James W Simpkins. (1998) Effects of gender and estradiol treatment on focal brain ischemia. Brain Research 784:1-2, 321-324
CrossRef393
June E Eichner, Hong Qi, William E Moore, Eliot Schechter. (1998) Iron measures in coronary angiography patients. Atherosclerosis 136:2, 241-245
CrossRef394
(1998) Design of the Womenʼs Health Initiative Clinical Trial and Observational Study. Controlled Clinical Trials 19:1, 61-109
CrossRef395
M. Calvin, M. Dyson, J. Rymer, S.R. Young. (1998) The effects of ovarian hormone deficiency on wound contraction in a rat model. BJOG: An International Journal of Obstetrics and Gynaecology 105:2, 223-227
CrossRef396
J. H. Pickar, R. A. Wild, B. Walsh, E. Hirvonen, R. A. Lobo. (1998) Effects of different hormone replacement regimens on − postmenopausal women with abnormal lipid levels. Climacteric 1:1, 26-32
CrossRef397
A. Cassidy, S. Milligan. (1998) How significant are environmental estrogens to women?. Climacteric 1:3, 229-242
CrossRef398
R. K. BHATHENA B. S. ANKLESARIA A. M.. (1998) The influence of medroxyprogesterone acetate on the effects of transdermal oestradiol replacement therapy on plasma lipids. Journal of Obstetrics & Gynaecology 18:2, 141-145
CrossRef399
J Alanko. (1998) Catechol estrogens as inhibitors of leukotriene synthesis. Biochemical Pharmacology 55:1, 101-104
CrossRef400
H. Kikuchi-Hayakawa, N. Onodera, S. Matsubara, E. Yasuda, Y. Shimakawa, F. Ishikawa. (1998) Effects of soya milk and Bifidobacterium-fermented soya milk on plasma and liver lipids, and faecal steroids in hamsters fed on a cholesterol-free or cholesterol-enriched diet. British Journal of Nutrition 79:01, 97
CrossRef401
Katherine Sherif, Harvey Kushner, Bonita E. Falkner. (1998) Sex hormone—binding globulin and insulin resistance in African-American women. Metabolism 47:1, 70-74
CrossRef402
Riitta Luoto, Satu Männistö, Erkki Vartiainen. (1998) Hormone replacement therapy and body size: How much does lifestyle explain?. American Journal of Obstetrics and Gynecology 178:1, 66-73
CrossRef403
Hiroko KIKUCHI-HAYAKAWA, Norie ONODERA, Satoshi MATSUBARA, Emi YASUDA, Osamu CHONAN, Rie TAKAHASHI, Fumiyasu ISHIKAWA. (1998) Effects of Soy Milk and Bifidobacterium Fermented Soy Milk on Lipid Metabolism in Aged Ovariectomized Rats.. Bioscience, Biotechnology, and Biochemistry 62:9, 1688-1692
CrossRef404
Gerd Hall, Ulla Pripp, Karin Schenck-Gustafsson, Britt-Marie Landgren. (1998) Longterm effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas 28:3, 235-242
CrossRef405
Yen le Tran, Alison Fung, Christine Forster. (1997) Role of gender and vascular endothelium in rat aorta response to 17 b -estradiol. Canadian Journal of Physiology and Pharmacology 75:12, 1393-1397
CrossRef406
E Glusa, T Gräser, S Wagner, M Oettel. (1997) Mechanisms of relaxation of rat aorta in response to progesterone and synthetic progestins. Maturitas 28:2, 181-191
CrossRef407
John Ciriello, M. Patricia Rosas-Arellano, L. Pastor Solano-Flores, Stefanie Roder. (1997) EFFECT OF GONADAL STEROIDS ON CENTRAL NEURONAL MECHANISMS CONTROLLING ARTERIAL PRESSURE IN THE FEMALE. Fundamental & Clinical Pharmacology 11:S1, 49s-52s
CrossRef408
Mine Inal, Emine Sunal, Güngör Kanbak, Sinan Zeytinoǧlu. (1997) Effects of postmenopausal hormone replacement and α-tocopherol on the lipid profiles and antioxidant status. Clinica Chimica Acta 268:1-2, 21-29
CrossRef409
Christa Hegele-Hartung, Karl-Heinrich Fritzemeier, Patrick Diel. (1997) Effects of a pure antiestrogen and progesterone on estrogen-mediated alterations of blood flow and progesterone receptor expression in the aorta of ovariectomized rabbits. The Journal of Steroid Biochemistry and Molecular Biology 63:4-6, 237-249
CrossRef410
U.-B. Kroon, L. Tengborn, H. Rita, A.-C. Backstrom. (1997) The effects of transdermal oestradiol and oral progestogens on haemostasis variables. BJOG: An International Journal of Obstetrics and Gynaecology 104:s16, 32-37
CrossRef411
Anette Tønnes Pedersen, Øjvind Lidegaard, Svend Kreiner, Bent Ottesen. (1997) Hormone replacement therapy and risk of non-fatal stroke. The Lancet 350:9087, 1277-1283
CrossRef412
James H. Pickar, David F. Archer. (1997) Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy?. American Journal of Obstetrics and Gynecology 177:5, 1178-1183
CrossRef413
Myra S. Hunter, Irene O'Dea, Nicky Britten. (1997) Decision-making and hormone replacement therapy: A qualitative analysis. Social Science & Medicine 45:10, 1541-1548
CrossRef414
James W. Simpkins, Gopal Rajakumar, Yu-Qi Zhang, Christopher E. Simpkins, David Greenwald, Chun J. Yu, Nicholas Bodor, Arthur L. Day. (1997) Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. Journal of Neurosurgery 87:5, 724-730
CrossRef415
Patricia T. Kelly. (1997) Breast Cancer Risk Assessment and Counseling: A Clinician's Guide. The Breast Journal 3:6, 311-316
CrossRef416
Winnie Leung, Franklin Goldberg, Bennie Zee, Ernest Sterns. (1997) Mammographic density in women on postmenopausal hormone replacement therapy. Surgery 122:4, 669-674
CrossRef417
Hirofumi Tagawa, Hiroaki Shimokawa, Tatsuya Tagawa, Mari Kuroiwa-Matsumoto, Yoshitaka Hirooka, Akira Takeshita. (1997) Short-Term Estrogen Augments Both Nitric Oxide-Mediated and Non-Nitric Oxide-Mediated Endothelium-Dependent Forearm Vasodilation in Postmenopausal Women. Journal of Cardiovascular Pharmacology 30:4, 481-488
CrossRef418
Hiroaki Kawano, Takeshi Motoyama, Kiyotaka Kugiyama, Osamu Hirashima, Masamichi Ohgushi, Hiromi Fujii, Hisao Ogawa, Hirofumi Yasue. (1997) Gender Difference in Improvement of Endothelium-Dependent Vasodilation After Estrogen Supplementation. Journal of the American College of Cardiology 30:4, 914-919
CrossRef419
Christopher S. Hayward, David C. Knight, Barry G. Wren, Raymond P. Kelly. (1997) Effect of hormone replacement therapy on non-invasive cardiovascular haemodynamics. Journal of Hypertension 15:9, 987-993
CrossRef420
Wen-Sen Lee, Justin A. Harder, Masao YoshizuMi, Mu-En Lee, Edgar Haber. (1997) Progesterone inhibits arterial smooth muscle cell proliferation. Nature Medicine 3:9, 1005-1008
CrossRef421
Darling, Giselle M., Johns, Jennifer A., McCloud, Philip I., Davis, Susan R., . (1997) Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women. New England Journal of Medicine 337:9, 595-601
Full Text422
Rene J. Alvarez, Sanford J. Gips, Nicanor Moldovan, Calvin C. Wilhide, Emily E. Milliken, Arthur T. Hoang, Ralph H. Hruban, Howard S. Silverman, Chi V. Dang, Pascal J. Goldschmidt-Clermont. (1997) 17β-Estradiol Inhibits Apoptosis of Endothelial Cells. Biochemical and Biophysical Research Communications 237:2, 372-381
CrossRef423
LORI A. BASTIAN, GRACE M. COUCHMAN, BARBARA K. RIMER, COLLEEN M. McBRIDE, JOHN R. FEAGANES, ILENE C. SIEGLER. (1997) Perceptions of Menopausal Stage and Patterns of Hormone Replacement Therapy Use. Journal of Women's Health 6:4, 467-475
CrossRef424
LINDA D. COWAN, OSCAR T. GO, BARBARA V. HOWARD, RICHARD B. DEVEREUX, DAVID J. PETTITT, RICHARD R. FABSITZ, ELISA T. LEE, THOMAS K. WELTY. (1997) Parity, Postmenopausal Estrogen Use, and Cardiovascular Disease Risk Factors in American Indian Women: The Strong Heart Study. Journal of Women's Health 6:4, 441-449
CrossRef425
Chakravarthi Rajkumar, Bronwyn A. Kingwell, James D. Cameron, Tamara Waddell, Rishi Mehra, Nicholas Christophidis, Paul A. Komesaroff, Barry McGrath, Garry L. Jennings, Krishnankutty Sudhir, Anthony M. Dart. (1997) Hormonal Therapy Increases Arterial Compliance in Postmenopausal Women. Journal of the American College of Cardiology 30:2, 350-356
CrossRef426
Paolo Madeddu, Costanza Emanueli, Maria Vittoria Varoni, Maria Piera Demontis, Vittorio Anania, Nicola Gorioso, Julie Chao. (1997) Regulation of bradykinin B 2 -receptor expression by oestrogen. British Journal of Pharmacology 121:8, 1763-1769
CrossRef427
K Bridget Brosnihan, Diann Weddle, Mary S. Anthony, Clara Heise, Ping Li, Carlos M. Ferrario. (1997) Effects of chronic hormone replacement on the renin–angiotensin system in cynomolgus monkeys. Journal of Hypertension 15:7, 719-726
CrossRef428
Stephen Scheidt. (1997) Changing Mortality from Coronary Heart Disease among Smokers and Nonsmokers over a 20-Year Interval. Preventive Medicine 26:4, 441-446
CrossRef429
ROBERTA B. NESS, LEWIS H. KULLER. (1997) Women's Health as a Paradigm for Understanding Factors that Mediate Disease. Journal of Women's Health 6:3, 329-336
CrossRef430
Willy Hanggi, Kurt Lippuner, Walter Riesen, Phillippe Jaeger, Martin H. Birkhauser. (1997) Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. BJOG: An International Journal of Obstetrics and Gynaecology 104:6, 708-717
CrossRef431
S. J. Hutchison, K. Sudhir, T. M. Chou, K. Chatterjee. (1997) Sex hormones and vascular reactivity. Herz 22:3, 141-150
CrossRef432
Susan R. Johnson. (1997) THE CLINICAL DECISION REGARDING HORMONE REPLACEMENT THERAPY. Endocrinology & Metabolism Clinics of North America 26:2, 413-435
CrossRef433
Y.Muscat Baron, M. Brincat, R. Galea. (1997) Carotid artery wall thickness in women treated with hormone replacement therapy. Maturitas 27:1, 47-53
CrossRef434
Ingemar Persson, Leif Bergkvist, Christina Lindgren, Jonathan Yuen. (1997) Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: Evidence of confounding by exposure characteristics. Journal of Clinical Epidemiology 50:5, 611-618
CrossRef435
Susan Davis. (1997) Cardiovascular disease prevention in postmenopausal women: a clinician's perspective. Maturitas 27:1, 1-3
CrossRef436
Jeffrey A. Dodge, Charles W. Lugar, Stephen Cho, Lorri L. Short, Masahiko Sato, Na N. Yang, Larry A. Spangle, Michael J. Martin, David L. Phillips, Andrew L. Glasebrook, John J. Osborne, Charles A. Frolik, Henry U. Bryant. (1997) Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. The Journal of Steroid Biochemistry and Molecular Biology 61:1-2, 97-106
CrossRef437
Rena Vassilopoulou-Sellin, Richard Theriault, Mary Jean Klein. (1997) Estrogen Replacement Therapy in Women with Prior Diagnosis and Treatment for Breast Cancer. Gynecologic Oncology 65:1, 89-93
CrossRef438
Pierantonio Visentin, Rossana Ciravegna, Fabrizio Fabris. (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26:3, 185-192
CrossRef439
Lauren Nathan and, Gautam Chaudhuri. (1997) ESTROGENS AND ATHEROSCLEROSIS. Annual Review of Pharmacology and Toxicology 37:1, 477-515
CrossRef440
Koh, Kwang Kon, Mincemoyer, Rita, Bui, Minh N., Csako, Gyorgy, Pucino, Frank, Guetta, Victor, Waclawiw, Myron, Cannon, Richard O., . (1997) Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal Women. New England Journal of Medicine 336:10, 683-691
Full Text441
David A. Decker, Jane E. Pettinga, Timothy C. Cox, John H. Burdakin, Ishmael A. Jaiyesimi, Pamela R. Benitez. (1997) Hormone Replacement Therapy in Breast Cancer Survivors. The Breast Journal 3:2, 63-68
CrossRef442
René Rizzoli, Jean-Philippe Bonjour. (1997) Hormones and bones. The Lancet 349, S20-S23
CrossRef443
GRAHAM A. COLDITZ, JOANN E. MANSON, SUSAN E. HANKINSON. (1997) The Nurses' Health Study: 20-Year Contribution to the Understanding of Health Among Women. Journal of Women's Health 6:1, 49-62
CrossRef444
Beda W. Hartmann, Johannes C. Huber. (1997) The mythology of hormone replacement therapy. BJOG: An International Journal of Obstetrics and Gynaecology 104:2, 163-168
CrossRef445
Schievink, Wouter I., . (1997) Intracranial Aneurysms. New England Journal of Medicine 336:1, 28-40
Full Text446
P M Dodson, E E Kritzinger. (1997) Medical cardiovascular treatment trials: Relevant to medical ophthalmology in 1997?. Eye 11:1, 3-11
CrossRef447
James H O’Keefe, Susie C Kim, Ralph R Hall, Vicki C Cochran, Stephanie L Lawhorn, Ben D McCallister. (1997) Estrogen Replacement Therapy After Coronary Angioplasty in Women. Journal of the American College of Cardiology 29:1, 1-5
CrossRef448
John G. Wilcox, Juliana Hwang, Howard N. Hodis, Alex Sevanian, Frank Z. Stanczyk, Rogerio A. Lobo. (1997) Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertility and Sterility 67:1, 57-62
CrossRef449
Raphael Jewelewicz. (1997) New developments in topical estrogen therapy. Fertility and Sterility 67:1, 1-12
CrossRef450
C. Christiansen. (1997) Sex steroids and the cardiovascular system. Osteoporosis International 7:S1, 8-11
CrossRef451
KAREN L. MILLER. (1996) Hormone Replacement Therapy in the Elderly. Clinical Obstetrics and Gynecology 39:4, 912-932
CrossRef452
Jerome L. Sullivan. (1996) Iron versus cholesterol—Perspectives on the iron and heart disease debate. Journal of Clinical Epidemiology 49:12, 1345-1352
CrossRef453
Steven H. Zuckerman, Susanne E. Ahmari, Nancy Bryan-Poole, Glenn F. Evans, Lorri Short, Andrew L. Glasebrook. (1996) Estriol: A potent regulator of TNF and IL-6 expression in a murine model of endotoxemia. Inflammation 20:6, 581-597
CrossRef454
William S. Weintraub, Nanette K. Wenger, Sam Parthasarathy, W.Virgil Brown. (1996) Hyperlipidemia versus iron overload and coronary artery disease: Yet more arguments on the cholesterol debate. Journal of Clinical Epidemiology 49:12, 1353-1358
CrossRef455
Jeanne E. O'Brien, Eric D. Peterson, Gordon P. Keeler, Lisa G. Berdan, E. Magnus Ohman, David P. Faxon, Alice K. Jacobs, Eric J. Topol, Robert M. Califf. (1996) Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. Journal of the American College of Cardiology 28:5, 1111-1118
CrossRef456
Henri Rozenbaum, Martin Birkhäuser, Coenraad De Nooyer, René Lambotte, Bruno Pornel, Hermann Schneider, John Studd. (1996) Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm TTS® 50). I. Tolerability, adhesion and efficacy. Maturitas 25:3, 161-173
CrossRef457
E. Schlicht, A. T. Teichmann. (1996) Kardiovaskuläre Erkrankungen und Hormonsubstitution in der Menopause. European Surgery 28:5, 266-270
CrossRef458
R Jeffrey Chang. (1996) Gonadotropin releasing hormone agonists and hormone replacement theory. Reproductive Medicine Review 5:03, 139
CrossRef459
Gian Franco Gensini, Serena Micheli, Domenico Prisco, Rosanna Abbate. (1996) MENOPAUSE AND RISK OF CARDIOVASCULAR DISEASE. Thrombosis Research 84:1, 1-19
CrossRef460
John A. Eden, Barry G. Wren. (1996) Hormone replacement therapy after breast cancer: a review. Cancer Treatment Reviews 22:5, 335-343
CrossRef461
Steven H Zuckerman, Nancy Bryan. (1996) Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis 126:1, 65-75
CrossRef462
Grodstein, Francine, Stampfer, Meir J., Manson, JoAnn E., Colditz, Graham A., Willett, Walter C., Rosner, Bernard, Speizer, Frank E., Hennekens, Charles H., . (1996) Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease. New England Journal of Medicine 335:7, 453-461
Full Text463
Masahiro Akishita, Yasuyoshi Ouchi, Hideyuki Miyoshi, Akira Orimo, Koichi Kozaki, Masato Eto, Michiro Ishikawa, Seungbum Kim, Kenji Toba, Hajime Orimo. (1996) Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta. Atherosclerosis 125:1, 27-38
CrossRef464
Peter Alexandersen, Jens Haarbo, Claus Christiansen. (1996) The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 125:1, 1-13
CrossRef465
H. Tineke Westerveld, Ellen Meijer, D.Willem Erkelens, Tjerk W.A. de Bruin. (1996) Postprandial reduction in high-density lipoprotein cholesterol concentrations in postmenopausal women: Improvement by 17β-estradiol. Metabolism 45:7, 827-832
CrossRef466
John R. Hilditch, Jacqueline Lewis, Alan H. Ross, Alice Peter, Barb van Maris, Edmée Franssen, Jocelyn Charles, Peter Norton, Earl V. Dunn. (1996) A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17β combined with an oral progestin on quality of life in postmenopausal women. Maturitas 24:3, 177-184
CrossRef467
Hiroshi Minaguchi, Tsuguo Uemura, Kazuhiro Shirasu, Akira Sato, Susumu Tsukikawa, Yoshito Ibuki, Hideki Mizunuma, Takeshi Aso, Takao Koyama, Shiro Nozawa, Hiroaki Ohta, Toshiyuki Ikeda, Koji Kusuhara, Kazuhiko Ochiai, Junzo Kato, Toshihiko Kinoshita, Kenichi Tanaka, Yusuke Minagawa, Takumi Kurabayashi, Masao Fukunaga. (1996) Effect of Estriol on Bone Loss in Postmenopausal Japanese Women: A Multicenter Prospective Open Study. Asia-Oceania Journal of Obstetrics and Gynaecology 22:3, 259-265
CrossRef468
John R. Hilditch, Jacqueline Lewis, Alan H. Ross, Alice Petera, Barb van Maris, Edmée Franssen, Jocelyn Charles, Peter Norton, Earl V. Dunn. (1996) A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17β combined with an oral progestin on quality of life in postmenopausal women. Maturitas 24:6, 177-184
CrossRef469
Michael W. Draper, David E. Flowers, William J. Huster, Julie A. Neild, Kristine D. Harper, Claude Arnaud. (1996) A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of Bone and Mineral Research 11:6, 835-842
CrossRef470
William D. Dupont, Walton D. Plummer. (1996) Understanding the relationship between relative and absolute risk. Cancer 77:11, 2193-2199
CrossRef471
T Tomita. (1996) Inhibition of cholesterylester accumulation by 17β-estradiol in macrophages through activation of neutral cholesterol esterase. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1300:3, 210-218
CrossRef472
Bruno de Lignieres. (1996) Hormone replacement therapy: clinical benefits and side-effects. Maturitas 23, S31-S36
CrossRef473
Åsa Stenberg, Gun Heimer, Ulf Ulmsten, Sven Cnattingius. (1996) Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 24:1-2, 31-36
CrossRef474
Philip J. DiSaia, Elizabeth A. Grosen, Tom Kurosaki, Maureen Gildea, Beth Cowan, Hoda Anton-Culver. (1996) Hormone replacement therapy in breast cancer survivors: A cohort study. American Journal of Obstetrics and Gynecology 174:5, 1494-1498
CrossRef475
Ron Tepper, Jacob Bar, Shmuel Goldberger, Jacob Fuchs, Yoram Beyth, Jardena Ovadia. (1996) The effect of medroxyprogesterone acetate and clomiphene citrate on platelet function in menopausal women. Maturitas 24:1-2, 51-56
CrossRef476
Reijo Punnonen, Hannu Jokela, Prasun Dastidar, Risto Aine, Pekka Laippala. (1996) Estrogen-progestin replacement therapy and atherosclerosis. Maturitas 23, S61-S64
CrossRef477
Kathryn M. King. (1996) Estrogen replacement therapy and coronary heart disease in postmenopausal women. Health Care for Women International 17:3, 247-254
CrossRef478
S. Lahdenperä, J. Puolakka, T. Pyörälä, H. Luotola, M-R. Taskinen. (1996) Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens. Atherosclerosis 122:2, 153-162
CrossRef479
Todd B. Seto, Deborah A. Taira, Roger B. Davis, Charles Safran, Russell S. Phillips. (1996) Effect of physician gender on the prescription of estrogen replacement therapy. Journal of General Internal Medicine 11:4, 197-203
CrossRef480
J STEVENSON. (1996) Handling hormone replacement therapy: key issues for the prescriber. European Journal of Obstetrics & Gynecology and Reproductive Biology 64, S25-S27
CrossRef481
Franca Citarella, Silvia Misiti, Angelina Felici, Antonella Farsetti, Alfredo Pontecorvi, Antonio Fantoni. (1996) Estrogen induction and contact phase activation of human factor XII. Steroids 61:4, 270-276
CrossRef482
Elizabeth Barrett-Connor. (1996) The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Maturitas 23:2, 227-234
CrossRef483
Henry U. Bryant, Andrew L. Glasebrook, Na N. Yang, Masahiko Sato. (1996) A pharmacological review of raloxifene. Journal of Bone and Mineral Metabolism 14:1, 1-9
CrossRef484
Hartmut Hanke, Sybille Hanke, Birgit Bruck, Ute Brehme, Natalia Gugel, Gerald Finking, Alfred O. Mück, Friedrich W. Schmahl, Vinzenz Hombach, Rainer Haasis. (1996) Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis 121:1, 129-138
CrossRef485
P. Lips. (1996) Prevention of hip fractures: Drug therapy. Bone 18:3, S159-S163
CrossRef486
George C. Wellman, Joseph E. Brayden, Mark T. Nelson. (1996) A PROPOSED MECHANISM FOR THE CARDIOPROTECTIVE EFFECT OF OESTROGEN IN WOMEN: ENHANCED ENDOTHELIAL NITRIC OXIDE RELEASE DECREASES CORONARY ARTERY REACTIVITY. Clinical and Experimental Pharmacology and Physiology 23:3, 260-266
CrossRef487
Faye J. LeBoeuf, Stefanie G. Carter. (1996) Discomforts of the Perimenopause. Journal of Obstetric, Gynecologic, <html_ent glyph="@amp;" ascii="&"/> Neonatal Nursing 25:2, 173-180
CrossRef488
Elisabeth Stadberg, Lars-Åke Mattsson, Margareta Uvebrant. (1996) 17β-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 23:1, 31-39
CrossRef489
Lars Bjørn Jensen, Jørgen Hilden. (1996) Sociological and behavioural characteristics of perimenopausal women with an express attitude to hormone substitution therapy. Maturitas 23:1, 73-83
CrossRef490
M Tang. (1996) Estrogens protect against hydrogen peroxide and arachidonic acid induced DNA damage. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1299:2, 155-159
CrossRef491
MURRAY FREEDMAN. (1996) Postmenopausal hormone replacement therapy and cardiovascular disease risk. Medicine & Science in Sports & Exercise 28:1, 17,18
CrossRef492
Anne A. Moore, Melinda Dunham Noonan. (1996) A Nurse's Guide to Hormone Replacement Therapy. Journal of Obstetric, Gynecologic, <html_ent glyph="@amp;" ascii="&"/> Neonatal Nursing 25:1, 24-31
CrossRef493
Gail L. Kongable, Giuseppe Lanzino, Teresa P. Germanson, Laura L. Truskowski, Wayne M. Alves, James C. Torner, Neal F. Kassell. (1996) Gender-related differences in aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery 84:1, 43-48
CrossRef494
Donna B Jeffe, Michael Freiman, Edwin B Fisher. (1996) Womenʼs Reasons for Using Postmenopausal Hormone Replacement Therapy: Preventive Medicine or Therapeutic Aid?. Menopause 3:2, 106-116
CrossRef495
Theodor H. Lippert, Harald Seeger, Alfred O. Mueck, Hartmut Hanke, Rainer Haasis. (1996) Effect of Estradiol, Progesterone, and Progestogens on Calcium Influx in Cell Cultures of Human Vessels. Menopause 3:1, 33-37
CrossRef496
Leif Bungum, Knut Kvernebo, Pal Oian, Jan Martin Maltau. (1996) Laser doppler-recorded reactive hyperaemia in the forearm skin during the menstrual cycle. BJOG: An International Journal of Obstetrics and Gynaecology 103:1, 70-75
CrossRef497
Sanjay Vyas, Kevin Gangar. (1995) Postmenopausal oestrogens and arteries. BJOG: An International Journal of Obstetrics and Gynaecology 102:12, 942-946
CrossRef498
P. J. Keller. (1995) Hormonsubstitution in der Postmenopause. Archives of Gynecology and Obstetrics 256:S1, S193-S197
CrossRef499
J. Alan Herd, Antonio M. Gotto. (1995) Does post-menopausal hormone-replacement therapy increase risk for breast cancer? A perspective on the findings of the nurses' health study. Pharmacological Research 32:6, 331-333
CrossRef500
(1995) Breast Cancer and Hormone-Replacement Therapy. New England Journal of Medicine 333:20, 1355-1358
Full Text501
Philip J. Disaia, Elizabeth A. Grosen, Franco Odicino, Beth Cowan, Sergio Pecorelli, Alan G. Wile, William T. Creasman. (1995) Replacement therapy for breast cancer survivors. A pilot study. Cancer 76:S10, 2075-2078
CrossRef502
B. Pornel, A.R. Genazzani, D. Costes, M.P. Dain, L. Lelann, C. Vandepol. (1995) Efficacy and tolerability of Menorest® 50 compared with estraderm® TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study. Maturitas 22:3, 207-218
CrossRef503
Fidelma P. Dunne, Penny Elliot, Michael D. Gammage, Terence Stallard, Tracy Ryan, Michael C. Sheppard, Paul M. Stewart. (1995) Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism. Clinical Endocrinology 43:5, 623-629
CrossRef504
Lars-Olof Wollter-Svensson, Elisabeth Stadberg, Kerstin Andersson, Lars-Åke Mattsson, Viveca Odlind, Ingemar Persson. (1995) Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism. Maturitas 22:3, 199-205
CrossRef505
GREGORY Y. H. LIP, GARETH BEEVERS, JOHN ZARIFIS. (1995) Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint. Journal of Internal Medicine 238:5, 389-399
CrossRef506
Sarah A. Samaan, Michael H. Crawford. (1995) Estrogen and cardiovascular function after menopause. Journal of the American College of Cardiology 26:6, 1403-1410
CrossRef507
A. Chandrasekaran, M. Osman, P. Raveendranath, K. Chan, J. A. Scatina, S. F. Sisenwine. (1995) Characterization of metabolites of Δ8,9-dehydroestrone in dogs. Journal of Mass Spectrometry 30:10, 1505-1511
CrossRef508
Marco Gambacciani, Adriana Spinetti, Roberto Orlandi, Laura Piaggesi, Barbara Cappagli, Carlo Weiss, Massimo Ciaponi, Andrea Riccardo Genazzani. (1995) Effects of a new estrogen/progestin combination in the treatment of postmenopausal syndrome. Maturitas 22:2, 115-120
CrossRef509
J.W.W. Studd, K. McCarthy, D. Zamblera, H.G. Burger, S. Silberberg, B. Wren, M.P. Dain, L.Le Lann, C. Vandepol. (1995) Efficacy and tolerance of Menorest® compared to Premarin® in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study. Maturitas 22:2, 105-114
CrossRef510
Julia M. Shelley, Anthony M. A. Smith, Emma Dudley, Lorraine Dennerstein. (1995) Use of hormone replacement therapy by Melbourne women. Australian Journal of Public Health 19:4, 387-392
CrossRef511
Carol A. Derby, Anne Lamont Hune, Janice B. McPhillips, ]Marilyn McFarland Barbour, Richard A. Carleton. (1995) Prior and current health characteristics of postmenopausal estrogen replacement therapy users compared with nonusers. American Journal of Obstetrics and Gynecology 173:2, 544-550
CrossRef512
A R Folsom, P J Mink, T A Sellers, C P Hong, W Zheng, J D Potter. (1995) Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women.. American Journal of Public Health 85:8 Pt 1, 1128-1132
CrossRef513
S. TONSTAD, L. OSE, C. GØRBITZ, O. DJØSELAND, J. M. BARD, J. C. FRUCHART. (1995) Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolemia among postmenopausal women. Journal of Internal Medicine 238:1, 39-47
CrossRef514
Florence A. Trémollieres, Jean-Michel Pouilles, Claude A. Ribot. (1995) A prospective two-year study of progestin given alone in postmenopausal women: Effect on lipid and metabolic parameters. American Journal of Obstetrics and Gynecology 173:1, 85-89
CrossRef515
D.Paul Shackelford, Matthew K. Hoffman, Paul R. Kramer, Matthew F. Davies, Paul F Kaminski. (1995) Evaluation of preoperative cardiac risk index values in patients undergoing vaginal surgery. American Journal of Obstetrics and Gynecology 173:1, 80-84
CrossRef516
Davidson, Nancy E., . (1995) Hormone-Replacement Therapy — Breast versus Heart versus Bone. New England Journal of Medicine 332:24, 1638-1639
Full Text517
Pernille Holm, Henrik Ø. Andersen, Børge G. Nordestgaard, Birgit Fischer Hansen, Knud Kjeldsen, Steen Stender. (1995) Effect of oestrogen replacement therapy on development of experimental arteriosclerosis: A study in transplanted and balloon-injured rabbit aortas. Atherosclerosis 115:2, 191-200
CrossRef518
J.F. Apperley, N. Reddy. (1995) Mechanism and management of treatment-related gonadal failure in recipients of high dose chemoradiotherapy. Blood Reviews 9:2, 93-116
CrossRef519
L. FALKON, M. GARI, J. L. GARCIA MORA, J. CALAF, J. RODRIGUEZ ESPINOSA, A. OLIVER, J. FONTCUBERTA. (1995) The effect of endogenous oestradiol levels on protein S concentration during a menstrual cycle and after GnRH analogues and gonadotropin therapy. British Journal of Haematology 90:2, 438-441
CrossRef520
Reijo H. Punnonen, Hannu A. Jokela, Prasun S. Dastidar, Maritta Nevala, Pekka J. Laippala. (1995) Combined oestrogen-progestin replacement therapy prevents atherosclerosis in postmenopausal women. Maturitas 21:3, 179-187
CrossRef521
C. MARY BEARD, CYNTHIA S. CROWSON, GEORGE D. MALKASIAN, W. MICHAEL O'FALLON, L. JOSEPH MELTON. (1995) Cardiovascular Disease and Cancer Risk Following Bilateral Oophorectomy: A Population-Based Study in Rochester, Minnesota. Journal of Women's Health 4:2, 133-141
CrossRef522
K. Lih-Mei Liao, Myra Hunter, John Weinman. (1995) Health-related behaviours and their correlates in a general population sample of 45-year old women. Psychology & Health 10:3, 171-184
CrossRef523
Peter M. Tiidus. (1995) Can Estrogens Diminish Exercise Induced Muscle Damage?. Canadian Journal of Applied Physiology 20:1, 26-38
CrossRef524
Edward G. Lufkin, Steven J. Ory. (1995) Postmenopausal estrogen therapy, 1995. Trends in Endocrinology & Metabolism 6:2, 50-54
CrossRef525
Dadin Fu, Conrad A. Hornick. (1995) Modulation of lipid metabolism at rat hepatic subcellular sites by female sex hormones. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1254:3, 267-273
CrossRef526
Franz Krempler, Selma M. Soyal, Wolfgang Patsch. (1995) Postmenopausal Hormone-Replacement Therapy and Cardiovascular Risk. Annals of Medicine 27:2, 149-156
CrossRef527
Robert A. Wild, E.Laurette Taylor, Allen Knehans. (1995) The gynecologist and the prevention of cardiovascular disease. American Journal of Obstetrics and Gynecology 172:1, 1-13
CrossRef528
Gouri Shanker, Mary Sorci-Thomas, Michael R. Adams. (1995) Estrogen modulates the inducible expression of platelet-derived growth factor mrna by monocyte/macrophages. Life Sciences 56:7, 499-507
CrossRef529
Phillip M. Sarrel. (1995) How Progestins Compromise the Cardioprotective Effects of Estrogens. Menopause 2:4, 187-190
CrossRef530
Charles L Loprinzi, Prema P. Peethambaram. (1995) Management of Menopausal Symptoms in Breast Cancer Patients. Annals of Medicine 27:6, 653-656
CrossRef531
C. Lladó-Carbonell, M. Sentí-Clapes, J. Rubiés-Prat, O. Arango-Toro, A. Gelabert-Mas. (1995) Serum Lipoprotein Changes after Orchidectomy and Treatment with Oestrogens and Luliberin Analogues in Male Sprague-Dawley Rats. Clinical Chemistry and Laboratory Medicine 33:1, 5-10
CrossRef532
Masahiko Sato, Andrew L. Glasebrook, Henry U. Bryant. (1994) Raloxifene: A selective estrogen receptor modulator. Journal of Bone and Mineral Metabolism 12:S2, S9-S20
CrossRef533
John D. Termine. (1994) Therapy for postmenopausal osteoporosis based on fundamental disease etiology and pathophysiology. Journal of Bone and Mineral Metabolism 12:S2, S25-S28
CrossRef534
Gordana M. Prelevic, Teodora Beljic. (1994) The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women. Maturitas 20:1, 37-44
CrossRef535
Timothy A. Welborn, Matthew W. Knuiman, Nick Ward, Davina E. Whittall. (1994) Serum insulin is a risk marker for coronary heart disease mortality in men but not in women. Diabetes Research and Clinical Practice 26:1, 51-59
CrossRef536
M. J. VAN DER MOOREN, M. G. A. J. WOUTERS, H. J. BLOM, L. A. SCHELLEKENS, T. K. A. B. ESKES, R. ROLLAND. (1994) Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. European Journal of Clinical Investigation 24:11, 733-736
CrossRef537
Myra S. Hunter, K.Lih Mei Liao. (1994) Intentions to use hormone replacement therapy in a community sample of 45-year-old women. Maturitas 20:1, 13-23
CrossRef538
S. G. Norman, J. W. W. Studd. (1994) A survey of views on hormone replacement therapy. BJOG: An International Journal of Obstetrics and Gynaecology 101:10, 879-887
CrossRef539
VALERIE A. McKEON. (1994) Hormone Replacement Therapy: Evaluating the Risks and Benefits. Journal of Obstetric, Gynecologic, <html_ent glyph="@amp;" ascii="&"/> Neonatal Nursing 23:8, 647-657
CrossRef540
J.Y. Gillet, G. Andre, B. Faguer, R. Erny, M. Buvat-Herbaut, M.A. Domin, J.M. Kuhn, B. Hedon, E. Drapier-Faure, J. Barrat, P. Lopes, G. Magnin, J.J. Leng, M.A. Bruhat, E. Philippe. (1994) Induction of amenorrhea during hormone replacement therapy: Optimal micronized progesterone dose. A multicenter study. Maturitas 19:2, 103-115
CrossRef541
JOHN P. BILEZIKIAN. (1994) Major Issues Regarding Estrogen Replacement Therapy in Postmenopausal Women. Journal of Women's Health 3:4, 273-282
CrossRef542
Wendy W. Livingston, Joseph M. Healy, Harmon S. Jordan, Cheryl K. Warner, James L. Zazzali. (1994) Assessing the needs of women and clinicians for the management of menopause in an HMO. Journal of General Internal Medicine 9:7, 385-389
CrossRef543
Marius J. van der Mooren, Jacqueline de Graaf, Pierre N.M. Demacker, Anton F.J. de Haan, Rune Rolland. (1994) Changes in the low-density lipoprotein profile during 17β-estradiol-dydrogesterone therapy in postmenopausal women. Metabolism 43:7, 799-802
CrossRef544
Amy Cheang, Regine Sitruk-Ware, Goran Samsioe. (1994) Transdermal oestradiol and cardiovascular risk factors. BJOG: An International Journal of Obstetrics and Gynaecology 101:7, 571-581
CrossRef545
Marilyn E. Miller, Graça M. Dores, Susan L. Thorpe, Wallace L. Akerley. (1994) Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thrombosis Research 74:6, 577-594
CrossRef546
P. Eberling, V.A. Koivisto. (1994) Physiological importance of dehydroepiandrosterone. The Lancet 343:8911, 1479-1481
CrossRef547
K.S. Joseph. (1994) The evolution of clinical practice and time trends in drug effects. Journal of Clinical Epidemiology 47:6, 593-598
CrossRef548
George I. Gorodeski. (1994) Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. Experimental Gerontology 29:3-4, 357-375
CrossRef549
Masahiko Sato, Cindy McClintock, John Kim, Charles H. Turner, Henry U. Bryant, David Magee, Charles W. Slemenda. (1994) Dual-energy X-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. Journal of Bone and Mineral Research 9:5, 715-724
CrossRef550
Ascherio, Alberto, Willett, Walter C., . (1994) Are Body Iron Stores Related to the Risk of Coronary Heart Disease?. New England Journal of Medicine 330:16, 1152-1154
Full Text551
Wood, Alastair J.J., , Belchetz, Paul E.. (1994) Hormonal Treatment of Postmenopausal Women. New England Journal of Medicine 330:15, 1062-1071
Full Text552
Marie L. Foegh, Satish Asotra, Marcus H. Howell, Peter W. Ramwell. (1994) Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. Journal of Vascular Surgery 19:4, 722-726
CrossRef553
S. Palacios, C. Menendez, A.R. Jurado, J.C. Vargas. (1994) Effects of oestradiol administration via different routes on the lipid profile in women with bilateral oophorectomy. Maturitas 18:3, 239-244
CrossRef554
A. Porcile, E. Gallardo, P. Onetto, D. Schächter. (1994) Very low estrogen-desogestrel contraceptive in perimenopausal hormonal replacement. Maturitas 18:2, 93-103
CrossRef555
Jan A. Gevers Leuven. (1994) Sex steroids and lipoprotein metabolism. Pharmacology & Therapeutics 64:1, 99-126
CrossRef556
Helen Wiseman, Peter Quinn. (1994) The Antioxidant Action of Synthetic Oestrogens Involves Decreased Membrane Fluidity: Relevance to Their Potential Use as Anticancer and Cardioprotective Agents Compared to Tamoxifen?. Free Radical Research 21:3, 187-194
CrossRef557
Douglas J. Marchant. (1994) Supplemental estrogen replacement. Cancer 74:S1, 512-517
CrossRef558
Maurizio R. Soma, Michele Meschia, Fiorenza Bruschi, Joel D. Morrisett, Rodolfo Paoletti, Remo Fumagalli, PierGiorgio Crosignani. (1994) Hormonal agents used in lowering lipoprotein(a). Chemistry and Physics of Lipids 67-68, 345-350
CrossRef559
Joanne Shay, Judit Futo, Nancy Badrov, Jonathan Moss. (1994) Estrogen withdrawal selectively increases serotonin reactivity in rabbit basilar artery. Life Sciences 55:13, 1071-1081
CrossRef560
Kenji Nakai, Chuichi Itoh, Kazuhiko Hotta, Tomonori Itoh, Masao Yoshizumi, Katsuhiko Hiramori. (1994) Estradiol-17β regulates the induction of VCAM-1 mRNA expression by interleukin-1β in human umbilical vein endothelial cells. Life Sciences 54:13, PL221-PL227
CrossRef561
Ewa Radwanska. (1993) The role of reproductive hormones in vascular disease and hypertension. Steroids 58:12, 605-610
CrossRef562
(1993) Vitamin E and the Risk of Coronary Disease. New England Journal of Medicine 329:19, 1424-1426
Full Text563
Silvano Adami, Maurizio Rossini, Nicoletta Zamberlan, Francesco Bertoldo, Romolo Dorizzi, Vincenzo Lo Cascio. (1993) Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women. Maturitas 17:3, 191-196
CrossRef564
C. Richard Conti. (1993) Editor's note: Estrogen therapy for the prevention of coronary heart disease: What are the facts?. Clinical Cardiology 16:10, 699-700
CrossRef565
Hannia Campos, Frank M. Sacks, Brian W. Walsh, Isaac Schiff, Mary Ann O'Hanesian, Ronald M. Krauss. (1993) Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism 42:9, 1153-1158
CrossRef566
E.J. Brunner, M.G. Marmot, I.R. White, J.R. O'Brien, M.D. Etherington, B.M. Slavin, E.M. Kearney, G. Davey Smith. (1993) Gender and employment grade differences in blood cholesterol, apolipoproteins and haemostatic factors in the Whitehall II study. Atherosclerosis 102:2, 195-207
CrossRef567
Carol A. Shively, Sarah S. Knox, Barbara B. Sherwin, Brian W. Walsh, Peter W.F. Wilson. (1993) Sex steroids, psychosocial factors, and lipid metabolism. Metabolism 42:9, 16-24
CrossRef568
Helen Wood, Rebekah Wang-Cheng, Ann Butler Nattinger. (1993) Postmenopausal hormone replacement. Journal of General Internal Medicine 8:8, 451-458
CrossRef569
R. Gundle, A.H.R.W. Simpson. (1993) Should women attending fracture clinics be counselled about osteoporosis?. Injury 24:7, 441-442
CrossRef570
G.M.C. Rosano, P.M. Sarrel, P.A. Poole-Wilson, P. Collins. (1993) Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. The Lancet 342:8864, 133-136
CrossRef571
Gerald B. Phillips. (1993) Relationship of serum sex hormones to coronary heart disease. Steroids 58:6, 286-290
CrossRef572
Stampfer, Meir J.Hennekens, Charles H.Manson, JoAnn E.Colditz, Graham A.Rosner, BernardWillett, Walter C.. (1993) Vitamin E Consumption and the Risk of Coronary Disease in Women. New England Journal of Medicine 328:20, 1444-1449
Full Text573
Lars-Ake Mattsson, Goran Samsioe, Bo Schoultz, Margareta Uvebrant, Ingela Wiklund. (1993) Transdermally administered oestradiol combined with oral medroxyprogesterone acetate: the effects on lipoprotein metabolism in postmenopausal women. BJOG: An International Journal of Obstetrics and Gynaecology 100:5, 450-453
CrossRef574
P. Collins, G.M.C. Rosano, C. Jiang, D. Lindsay, P.A. Poole-Wilson, P.M. Sarrel. (1993) Cardiovascular protection by oestrogen—a calcium antagonist effect?. The Lancet 341:8855, 1264-1265
CrossRef575
Amanda J. Lee, Gordon D. O. Lowe, William C. S. Smith, Hugh Tunstall-Pedoe. (1993) Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. British Journal of Haematology 83:4, 616-621
CrossRef576
Douglas J. Marchant. (1993) Estrogen-replacement therapy after breast cancer risks versus benefits. Cancer 71:S6, 2169-2176
CrossRef577
Susan K. Marten. (1993) Complications of Menopause and the Risks and Benefits of Estrogen Replacement Therapy. Journal of the American Academy of Nurse Practitioners 5:2, 55-61
CrossRef578
Peter Smith, Gun Heimer, Marianne Lindskog, Ulf Ulmsten. (1993) Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 16:2, 145-154
CrossRef579
Giske Ursin, DarcyV. Spicer, MalcolmC. Pike, AvrumZ. Bluming, A. Fugh-Berman, S.S. Epstein. (1993) Tamoxifen and prevention. The Lancet 341:8846, 693-695
CrossRef580
Caroline J. Lundell. (1993) Spontaneous Hepatic Rupture in Postmenopausal Women Receiving Oral Estrogen Replacement
. Journal of Vascular and Interventional Radiology 4:2, 245-249
CrossRef581
Philip J. Disaia. (1993) Hormone-replacement therapy in patients with breast cancer: A reappraisal. Cancer 71:S4, 1490-1500
CrossRef582
D Chaouat, Y Tsouderos. (1993) Les thérapeutiques médicamenteuses préventives de l'ostéoporose postménopausique. La Revue de Médecine Interne 14:9, 877-887
CrossRef583
Graça M. Dores, Marilyn E. Miller, Susan L. Thorpe. (1993) Platelet adhesion at low shear rate: Study of a normal population. Thrombosis Research 69:2, 173-184
CrossRef584
B.J. Oddens, M.J. Boulet, P. Lehert, A.P. Visser. (1992) Has the climacteric been medicalized? A study on the use of medication for climacteric complaints in four countries. Maturitas 15:3, 171-181
CrossRef585
J. Coope, J. Marsh. (1992) Can we improve compliance with long-term HRT?. Maturitas 15:2, 151-158
CrossRef586
Amanda J. Lee, Gordon D.O. Lowe, William C.S. Smith, Tunstall-Pedoe Hugh. (1992) Plasma fibrinogen: Its relationship with oral contraception, the menopause, and hormone replacement therapy. Clinical Biochemistry 25:5, 403-405
CrossRef587
Patricia A. Buffler, Julie E. Buring. (1992) Women and health. Annals of Epidemiology 2:5, 759-760
CrossRef588
Wood, Alastair J.J., , Riggs, B. Lawrence, Melton, L. Joseph III, . (1992) The Prevention and Treatment of Osteoporosis. New England Journal of Medicine 327:9, 620-627
Full Text589
Charles K. Francis, Harriet P. Dustan, L.Julian Haywood, Tom Pearson, Mark B. Wenneker. (1992) Task force 1: Scope of the problem. Journal of the American College of Cardiology 19:7, 1449-1460
CrossRef590
Manson, JoAnn E., Tosteson, Heather, Ridker, Paul M., Satterfield, Suzanne, Hebert, Patricia, O'Connor, Gerald T., Buring, Julie E., Hennekens, Charles H., . (1992) The Primary Prevention of Myocardial Infarction. New England Journal of Medicine 326:21, 1406-1416
Full Text591
Jean Ginsburg, Stanley Okolo, Paul Hardiman, JacobC. Seidell. (1992) Coronary heart disease in women. The Lancet 339:8799, 986-987
CrossRef592
H. O. D. CRITCHLEY, E. A. FARRELL Director, D. L. HEALY. (1992) Safety of post-menopausal hormone replacement. Australian and New Zealand Journal of Medicine 22:2, 103-105
CrossRef593
(1992) Postmenopausal Estrogen Therapy and Cardiovascular Disease. New England Journal of Medicine 326:10, 705-708
Full Text594
B.A Reid, K.F Gangar. (1992) Catamenial epilepsy and goserelin. The Lancet 339:8787, 253
CrossRef595
Walsh, Brian W., Schiff, Isaac, Rosner, Bernard, Greenberg, Louise, Ravnikar, Veronica, Sacks, Frank M., . (1991) Effects of Postmenopausal Estrogen Replacement on the Concentrations and Metabolism of Plasma Lipoproteins. New England Journal of Medicine 325:17, 1196-1204
Full Text596
(1991) More than hot flushes. The Lancet 338:8772, 917-918
CrossRef597
Goldman, Lee, Tosteson, Anna N.A., . (1991) Uncertainty about Postmenopausal Estrogen. New England Journal of Medicine 325:11, 800-802
Full Text
- Letters
